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ABSTRACT  
Immunosuppression is a hallmark of human immunodeficiency virus-1 (HIV-1) infection. 
Upon binding to cluster of differentiation (CD) 4 receptor via trimeric glycoprotein (Gp) 120, 
HIV-1 enters and multiplies in CD4+ T cells, leading to the death of these cells. CD4+ T helper 
(Th) cells are required for the generation and maintenance of CD8+ T cells, which are crucial to 
control HIV-1 proliferation. The stimulation of HIV-1-specific CD8+ T cell responses in CD4-
deficient environment is a major scientific challenge. In addition, dendritic cells (DCs) 
expressing C-type lectin and dendritic cell-specific intercellular adhesion molecule-3-grabbing 
non-integrin (DC-SIGN) with high affinity for Gp120, appear to act as “Trojan horses”, 
facilitating the spread of HIV-1 from mucosal surfaces to T cells in lymph nodes, and these HIV-
1-infected T cells have been found to be impaired. Currently, highly active antiretroviral therapy 
(HAART) is the only means to halt progression of acquired immunodeficiency syndrome 
(AIDS). Although HAART suppresses viral replication and significantly improves prognosis, 
toxicity and cost of the treatment have become major limitations for its use. In addition, with 
long-term use, HAART also decreases HIV-1-specific CD4+ Th1 and CD8+ T cell responses, 
causing a functional decrease in capacity of HIV-1-capturing DCs in initiating adaptive immune 
responses. As a result, HIV patients are unable to eliminate infected cells and proviral latent 
reservoirs. Therefore, how to stimulate efficient CD8+ T cell responses in AIDS patients is one 
of the major challenges in HIV-1 patient therapy.  
 Previously, it was demonstrated that novel ovalbumin (OVA)-specific exosome (EXO)-
targeted CD4+ T cell vaccine (CD4+aTexo) was capable of stimulating CD4+ T cell-independent 
CD8+ T cell responses and antitumor immunity to a highly metastasizing tumor challenge in 
wild-type mice.  Since CD4+ T cells are killed by HIV-1, the present study proposed to use 
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active CD8+ T cells rather than active CD4+ T cells for vaccine development. First, OVA-
specific CD8+aTexo (OVA-aTexo) vaccine was prepared by pulsing concanavalin A (Con A)-
stimulated CD8+ T cells with OVA-pulsed DCs (DCOVA)-released exosomes (EXOOVA). In wild-
type mice, OVA-aTexo vaccine stimulated CD4-independent OVA-specific CD8+ T cell 
responses via CD40L and interleukin (IL)-2 signaling, and exosomal peptide major histo-
compatibility complex (pMHC)-I targeting. To further provide insight into whether CD8+aTexo 
vaccine induces similar cellular immune response in the context of human immune system, 
transgenic A2-Kb mice expressing !1 and !2 domains of human leukocyte antigen (HLA)-A2 
and !3 domain of mouse H2-Kb were used. Adenovirus (AdVGp120) expressing HIV-1 envelope 
protein Gp120 was used to transfect bone-marrow DCs to generate DC expressing Gp120 and 
DCGp120-released EXO were purified (EXOGp120). EXOGp120 were also purified from the culture 
supernatant of DC2.4Gp120-transfected cells. Next, Gp120-specific CD8+aTexo (Gp120-aTexo) 
vaccine was prepared by pulsing ConA-stimulated CD8+ T cells with EXOGp120. In wild-type and 
A2-Kb mice, Gp120-aTexo vaccine stimulated Gp120-specific effector and memory CD8+ 
cytotoxic T lymphocyte (CTL) responses, and provided preventive immunity to BL610-Gp120 
and BL6-10A2Kb/Gp120 tumor cells, respectively. Gp120-aTexo vaccine also provided 
therapeutic immunity against 3 and 6-day lung tumor metastasis in transgenic A2-Kb mice. 
Taken together, these results represent a novel approach to the induction of immunity for the 
treatment of AIDS patients with CD4+ T cell deficiency or for use in AIDS patients on HAART 
to clear virus-infected cells.  
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CHAPTER 1 
REVIEW OF THE LITERATURE     
1.1 Acquired immunodeficiency syndrome (AIDS) and limitations to current 
treatments 
 AIDS causes millions of deaths each year around the world (1). Human 
immunodeficiency virus type-1 (HIV-1) is the causative agent of this syndrome (2).  The 
virus enters the body by crossing the mucosal barrier and infecting cells bearing cluster of 
differentiation (CD) 4 receptors (3). A strong immune response mounts against HIV-1 
during the early stages of infection (see section 1.3.1 for details). However, the virus 
exhibits several protective mechanisms that prevent complete elimination. These 
protective mechanisms include integration of viral DNA into the host genome, extensive 
mutation of the viral DNA and depletion of crucial host immune cells (4). HIV-1 
infection is mainly characterized by a gradual depletion of CD4+ T cells (5), a key 
regulator of the adaptive immune response. HIV-1 also infects dendritic cells (DCs) via 
either the CD4 receptor and/or the DC specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN) receptor. Infection of these cells leads to development 
of tolerogenic DC (reviewed in (6)). Tolerogenic DCs are dysfunctional and unable to 
stimulate further immune responses. Consequently, infected individuals enter an immune-
suppressive state and become susceptible to cancers and opportunistic secondary 
infections.   
 To date, highly active antiretroviral therapy (HAART), which suppresses virus 
replication, is the only treatment available to stop disease progression in HIV-1-infected 
individuals (7). However, HAART is very expensive and has several direct side effects, 
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such as mitochondrial toxicity, pancreatitis, liver toxicity, and predisposition to coronary 
heart disease. In addition, HAART is only effective during the early infection stage when 
the viral DNA is rapidly replicating.  This therapy does control disease progression and 
increases HIV-1-specific CD4+ Th1 responses. However, in later stages of the infection, 
the virus becomes integrated into the host genome, thereby reducing its rate of replication 
and developing resistance against the treatment.  Therefore, HAART does not completely 
eliminate the pro-viral (latent) reservoir or residual viruses from patients.  This in turn 
leads to a decline in virus-specific CD4+ Th1 and CD8+ cytotoxic T cell (CTL) responses 
(8, 9).  
 Current HIV-1 vaccine protocols, which use viral proteins, plasmid DNA or 
recombinant viruses in the vaccines, only stimulate CD4+ T cell dependent CD8+ T cell 
responses (10). The result is limited to humoral and cellular immune responses against 
the initial viral epitopes. HIV-1 targets and depletes CD4+ T cells, and the virus is 
capable of rapid antigenic variation, as a result the host is unable to develop effective 
immune responses against subsequent epitopes. In addition, in the absence of a healthy 
CD4+ T cell population, stimulation of an efficient CD8+ T cell response becomes a 
major challenge. Due to these limitations, there is an immediate need to develop novel 
vaccine strategies (which enhance CTL responses and are able to rapidly respond to a 
broad range of viral recombinants) to control the progression of and/or prevent HIV-1 
infection.   
 
 
 
! $!
1.2 HIV-1 structure 
 HIV-1 belongs to the genus Lentivirus, which is a member of the Retroviridae 
family.  The viral particle is spherical in shape.  It consists of an inner core (the capsid) 
and an outer viral membrane (11). The inner core of HIV-1 consists of two copies of 9.7 
kb single-stranded RNA as genetic material (12) and enzymes, such as protease, integrase 
and reverse transcriptase, that are essential for replication of the virus. The outer viral 
membrane, known as the viral envelope, is derived from the plasma membrane of human 
cells and forms around the capsid as it is released from the cell. The HIV-1 genome 
encodes nine genes.  Three of these genes encode crucial structural gene products: gag, 
pol and env. ‘Gag’ gene products are precursors for viral capsid proteins, and are 
involved in packaging of the viral genome (13). The ‘pol’ gene products are precursors 
for several enzymes (reverse transcriptase and integrase), and are important for viral 
replication. The ‘env’ gene product glycoprotein (Gp) 160 is the precursor for the viral 
envelope proteins, Gp41 and Gp120 (14). In addition, the HIV-1 genome also encodes 
other accessory gene products, such as tat, rev, vpu, vpr, nef and vif, which help in viral 
replication (15).  
The viral membrane consists of a spherical lipid bilayer and contains about 14 
spikes, called Gp160 complexes (16). The mature Gp160 complex consists of three 
Gp120 subunits and three Gp41 subunits (17). The Gp120 subunits are exposed on the 
surface of the viral envelope while the Gp41 subunits are embedded within the 
membrane.  The Gp160 complex binds the CD4 receptor, thereby facilitating HIV-1 entry 
into target cells and subsequent release of the viral capsid into the host cytoplasm (18, 
19). Specifically, Gp120 forms a complex with the CD4 receptor with a strong affinity. 
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This causes a conformational change in Gp120, leading to exposure of Gp120 to the 
chemokine-binding domain of either of two co-receptors (C-X-C chemokine receptor 
(CXCR4) or C-C chemokine receptor (CCR)-5), and results in viral penetration into the 
cell (20, 21). Macrophage/monocyte/DC-tropic viruses use CCR5 as the co-receptor, 
whereas CD4+ T cell-tropic viruses use CXCR4 as the co-receptor. It has been reported 
that, in the process of HIV-1 transmission from mucosal surface to blood, the 
macrophage/monocyte/DC-tropic viruses can convert into CD4-tropic viruses (21, 22).  
One of the peculiar features of HIV-1 is the reverse transcriptase enzyme. This 
enzyme is highly error-prone in nature and lacks proof-reading activity (23). This results 
in a high rate of non-specific mutations being introduced into the HIV-1 genome during 
viral replication.  Mutations that arise in antigenic epitopes are often non-lethal and, as 
they present a novel epitope, these viruses are no longer recognized by the initial immune 
responses.  Therefore, generation of these mutations is part of the viral mechanism for 
evading immune responses. When HIV-1 infects a host, the viral RNA is converted into 
double-stranded DNA via the virus-encoded reverse transcriptase enzyme (24). HIV-1 
hijacks host nuclear import machinery to transport and integrate its double-stranded DNA 
into the genomic DNA. The integrated DNA or provirus template encodes virus 
structural, regulatory and other accessory proteins to generate new viral particles (25).   
Based on the analysis of genomic sequences, HIV-1 variants are categorized into 
three major phylogenetic groups, M (main), O (outlier) and N (non M/O). Group M 
viruses, which infect widely around the world, have the greatest genetic diversity, and are 
classified into nine subtypes or clades called (A-D, F-H, J and K) (26-29); clade-C 
viruses alone cause more than 80% of all HIV-1 infections.  Similar to group M, group O 
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viruses consist of diverse strains of viruses (forty-nine strains), but this group is not sub-
divided by clades (30). Group N, some time referred as ‘new’ group, viruses are more 
distinctive compared to group M and O, and rare viruses. Group N viruses are more 
common in Cameroon; only a few group N viruses have been isolated and characterized 
(31).  
 
1.3 HIV-1 pathogenesis  
The pathogenesis of HIV-1 infection is distinct from other viral infections in that 
the virus selectively depletes CD4+ T cells. HIV-1 infection also leads to the development 
of dysfunctional or tolerogenic DCs due to continuous exposure to viral proteins, 
particularly to Gp120. A stepwise progression of HIV-1 pathogenesis is discussed below.  
1.3.1 Early infection stage  
In most instances, the transmission of HIV-1 occurs through the mucosal barriers 
(32, 33). In the mucosa, HIV-1 multiplies in CD4, CCR5/CXCR4 and DC-SIGN 
receptor-expressing cells (34). Subsequently, within one week of exposure, HIV-1 enters 
into local draining lymph nodes (35-38) and later spreads throughout the body via the 
blood steam. Replication of HIV-1 peaks between 2 to 4 weeks after infection, just before 
the development of a virus-specific adaptive immune response (39). Strikingly, although 
all CD4+ T cells are susceptible to the viral infection, HIV-1-specific CD4+ T cells 
preferentially get infected when they interact with infected DCs (40). Thus, in HIV-1 
infection, viral antigen (Ag) presentation by DCs has both advantages and disadvantages. 
 After 8-12 weeks, in addition to other organs, HIV-1 preferentially spreads to gut-
associated lymphoid tissues, which are rich in CD4+ memory T cells. HIV-1 infects 
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CD4+/CXCR4 T cells and multiplies rapidly, which results in the death of >80% of gut-
associated CD4+ T cell population (41). Subsequently, virus particles enter into the blood 
stream and infect more and more target cells, reaching peak viremia. Consequent to viral 
multiplication and infection, the body responds promptly at the beginning of infection by 
developing both humoral and cellular immune responses, which lead to a drastic decrease 
in the viremia (42-44). During this early infection stage, the infected individuals 
gradually recover in 2 to 6 months (45). Nevertheless, the blood CD4+ T cell counts 
continue to drop to <200-400 cells/µl. 
1.3.2 Asymptomatic stage 
 A clinically asymptomatic stage, which follows the acute infectious stage, may 
extend up to 8-10 years, depending on the anti-viral immune status (HIV-1-specific 
CTLs, memory T cells and neutralizing antibodies (Abs)), host genetic composition, and 
virulence of the acquired HIV-1 strain (46, 47). All of these factors are known to 
contribute to the slower-progression of HIV-1 infection in infected individuals. In the 
asymptomatic stage, the number of viral RNA copies in the blood decreases due to the 
host’s immune response and due to the presence of virus-specific Abs in the serum. 
However, the virus replicates continuously in CD4+ T cells, leading to the generation of a 
multitude of HIV-1 mutants (48).  
1.3.3 Symptomatic stage and AIDS 
 HIV-1 mutants produced in the asymptomatic stage are capable of escaping from 
previously generated immune responses, which enables continuous HIV-1 replication in 
CD4+ T helper cells. CD4+ T helper cells are regarded as master regulators of the 
adaptive immune system, and without functional T helper cells HIV-1 patients become 
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completely immune-compromised. Consequently, HIV-1-infected individuals are highly 
susceptible to many opportunistic microbial infections, such as Mycobacterium 
tuberculosis and Candida species and herpes viruses, and more susceptible to 
development of many cancers. The affected patients commonly show symptoms of 
weight loss, repeated respiratory tract infections and skin rashes. (49) (50, 51). Finally, 
patients exhibit complex symptoms and signs of many diseases.  This condition is known 
as AIDS. AIDS patients usually die due to the secondary complications associated with 
the primary HIV-1 infection. 
 
1.4 Immune responses to HIV-1 infection 
 Depending on the genetic composition and immune status of an individual, both 
innate and adaptive immune responses control viral replication and spread. Upon HIV-1 
entry into the body, the innate immune response develops to control viral spread.  Later, 
HIV-1-specific cell-mediated and humoral immune responses develop to kill virally 
infected cells and neutralize cell-free virus, respectively.  
1.4.1 Innate immune responses   
The innate immune response is non-specific and is the immediate line of defense against 
invading pathogens. A variety of innate immune cells, such as natural killer (NK) cells 
and NK T cells, macrophages and DCs, contribute to the innate response to HIV-1 
infection. In acutely infected individuals, the innate response is characterized by 
increased levels of acute-phase proteins and cytokines, particularly interleukin-1 (IL-1) 
(52). As the infection progress, cytokines (IL-15, IL-18, IL-22, type-1 interferons (IFNs), 
IFN-! and tumor necrosis factors (TNF!)) and chemokines (ligand-C X C motif ligand 
! )!
10) levels also increase in the blood (53). Ironically, the magnitude of cytokine secretion, 
particularly IFNs, IL-15, IL-18, may support rather than control viral replication early 
after infection (54). NK and NK T cells have proven effective in reducing HIV-1 levels 
by killing virally infected cells and producing anti-viral chemokines (55). Macrophages 
have been shown to have less effect in controlling HIV-1 infection; instead they increase 
viral spread to T cells during Ag-presentation (56, 57). DCs play a multifaceted role 
during HIV-1 infection. DC numbers drastically decrease in the acute phase (58). Unlike 
with other viral infections, during HIV-1 infection, infected DCs show incomplete 
activation, and secrete lower levels of IL-12, although they retain the ability to secrete 
normal levels of IFNs (53). DCs also produce indoleamine 2,3 dioxygenase, which 
converts CD4+ helper T cells into regulatory T cells, which suppress virus-specific 
immune responses (59, 60). Furthermore, DCs are known to spread HIV-1 to T cells. 
Several possible mechanisms were proposed to explain DC-mediated HIV transmission. 
DCs transfer viral particles binding to cell surface (to DC-SIGN) receptors to T cells 
during DC-T cell contact in Ag-presentation. In addition, DCs transfer infection by an 
exocytic pathway, where DCs release HIV-1 associated exosomes. These exosomes 
transfer HIV-1 particle to CD4+ T cells by membrane binding and fusion (reviewed in 
(61, 62).Collectively, although the innate immune system responds strongly to HIV-1 
infection, by targeting CD4 receptors on immuno-regulatory cells, the virus is able to 
capitalize on many strategies, such as modulating the response of different immune cells, 
and regulating cytokine- and chemokine-expression profiles, to escape from innate 
immune control. 
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1.4.2 Humoral immune responses 
The humoral immune response in the form of Abs is crucial for neutralizing cell-
free viruses and for activating the cell-mediated Ab-dependent cytotoxicity effect to kill 
infected cells, thereby preventing the spread of infection. Production of HIV-1-specific 
Abs is usually detectable within 4-6 weeks after infection. Non-neutralizing Abs are first 
produced against the structural proteins, such as p24, p17 and Gag (63, 64), followed by 
neutralizing Abs against the envelope protein, Gp120 and Gp41. The neutralizing Abs 
produced during HIV-1 infection are predominantly specific to epitopes present in the 
variable (V) 3 domain and CD4- and CCR5/CXCR4-binding sites on Gp120, and Gp41 
trans-membrane domain. (65). During the early stage of infection, immunoglobulin (Ig) 
A, IgG and IgM Abs are produced (66). However, these Abs often exhibit narrow 
specificity. The Abs are only specific to the initial HIV-1 variant, and are not selected to 
recognize HIV-1 mutants, which are generated after each round of multiplication (67). 
One of the difficulties the immune system encounters, with respect to generating Abs 
against mutated forms of the initial HIV-1 strain is that the reduced CD4+ T cell 
population prevents efficient helper activity for maturation of new B cell populations. 
HIV-1 replication in the lymph node germinal centers leads to apoptosis of more than 
50% of B cells within first 10 weeks of infection (68). This also reduces generation of 
effective neutralizing Abs during the early infection stage. Continuous changes in the 
glycosylation sites and structure of Gp120 epitopes (69) prevent viral progeny from being 
recognized by existing neutralizing Abs (70). All these factors contribute to the humoral 
immune response to HIV-1 being inefficient at containing the infection.  
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1.4.3 Cell-mediated immune responses 
 The primary immune response is initiated upon exposure of the body to HIV-1. Ag-
presenting cells engulf the viral particles, then internalize, process and present viral 
peptides on human leukocyte antigen (HLA) MHC (major histocompatibility complex) 
class-I and-II molecules. DCs activate both HIV-1-specific CD4+ and CD8+ T cells, 
resulting in the development of virus-specific cell-mediated immune response. The 
activated HIV-1-specific CD8+ CTLs destroy virally infected cells, including infected 
CD4+ T cells (71), (72). In addition, CD8+ CTLs suppress HIV-1 replication and inhibit 
viral spread by secreting different types of cytokines (IFN-! and TNF-") and chemokines 
(73). This leads to a drastic decrease in the viral titer towards the end of acute infection 
stage. HIV-1 mainly infects and destroys CD4+ T cells, both effector and memory CD4+ 
T cells (74, 75). HIV-1 viral replication is highly efficient, using much of the host cell 
catabolic and metabolic resources, resulting in apoptosis of the host cell.  HIV-1-specific 
CD4+ T cells are particularly susceptible as they are in direct contact with the infected 
antigen presenting cells (APCs) during Ag presentation.  Mutations in antigenic epitopes, 
generated during HIV-1 replication within the APCs, result in new epitopes being 
presented on major histo-compatibility complex (MHC)-I and MHC-II complexes.  This 
prevents expansion and maturation of HIV-1-specific CD4+ and CD8+ T cells, as the 
appropriate epitope is no longer present on the APC (76-79). Continued T cell activation 
against newly generated HIV-1 mutant epitopes puts the patient’s immune system under 
constant immunological pressure. High levels of microbial components and inflammatory 
cytokines present in the blood of HIV-1 infected subjects’ increase the expression of 
programmed death-1 marker on monocytes, which is involved in apoptosis and negative 
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regulation of T cell activation, leading to CD4+ T cells dysfunction or tolerance (80). 
 Nevertheless, strong virus-specific CD8+ CTL responses are critical in controlling 
in HIV-1 infection and its progression (81, 82). The efficient CD8+ CTL response to 
many conserved HIV-1 immuno-dominant epitopes results in decreased viremia and 
disease progression (82).  Therefore, an effective vaccination strategy should aim to 
generate a strong CD8+ T cell response against multiple highly conserved epitopes of 
HIV-1 (83, 84). 
 
1.5 Immune responses to Gp120 
 As noted before, the trimeric Gp120 protein molecule is part of the spikes on the 
HIV-1 envelope (85). Key protein domains present on the Gp120 protein interact with 
specific regions present on CD4 and chemokine receptors. This interaction leads to 
conformational changes in both Gp120 and Gp41.  These conformational changes lead to 
HIV-1 virus entry into target cells. Based on the results of comparative sequence analysis, 
Gp120 is divided into five conserved (C) (C1-C5) and five variable segments (V1-V5). 
The conserved regions of Gp120 protein, C1-C5, are responsible for the non-covalent 
interactions between the three Gp120 subunits of the trimeric complex and with Gp41, 
resulting in Gp160. It has been reported that neutralizing Abs can bind to these conserved 
regions only when Gp120 is in its monomeric form (86).  This is likely because these 
epitopes are buried within the core of the complex. The variable regions of Gp120 
protein, particularly V1, V2 and V3, are present on the exposed area of Gp120. The V2 
region is a highly variable, whereas the V3 region consists of a few conserved sequences 
and is the target for most neutralizing Abs.  
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 During HIV-1 infection, polyclonal Abs are generated to various viral proteins. 
Only a small percentage of these Abs are specific to Gp120 and have neutralizing 
capacity (87). Neutralizing Abs to Gp120 are defined as being able to control HIV-1 
infection by binding cell-free HIV-1 (88) and/or being able to facilitate destruction of 
virally infected cells via Ab-dependent cell-mediated cytotoxicity or complement-
mediated cell lysis (89, 90).  Clinical studies, using various viral vectors, recombinant 
protein and adjuvant-enhanced Gp120 vaccines, have resulted in the generation of 
relatively effective cell-mediated immune responses as well as neutralizing Abs 
responses (reviewed in (91)).  
There are intrinsic limitations to Gp120 antigenic properties.  Although Gp120 
consists of potential epitopes for neutralizing Abs and CD8+ T cells, it has negative 
effects on activation of professional APCs, CD4+ T cells and B cells. Studies have shown 
that HIV-1 adapts several strategies to evade binding of neutralizing Abs to Gp120. More 
than 50% of this envelope protein surface is covered by carbohydrates, which are known 
as the glycan shield.  Due to the presence of this glycan shield, the neutralizing epitopes 
of Gp120 protein are often buried and not efficiently recognized by Abs (92). Gp120 is 
known to be a super Ag for B cell activation which results in T cell independent 
differentiation of B cells and spontaneous production of polyclonal non-specific Abs 
(93).  Furthermore, Gp120 is known to interact with the C-type lectin or DC-SIGN 
receptors of DCs, inducing development of tolerogenic DCs incapable of presenting Ag 
(94). Therefore, new approaches to vaccine development, which eliminate these 
limitations, are needed to control HIV replication.  Ideally these approaches should 
enhance virus-specific T cell responses. 
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1.6. HIV-1 vaccine development  
It has been more than 20 years since the eradication of smallpox. Through 
vaccination numerous diseases, including polio, rabies, measles, hepatitis B and 
influenza, have been controlled successfully. HIV-1’s unique properties, such as 
preferentially killing CD4+ cells and the establishment of latency in infected cells, are 
preventing development of an effective vaccine. The traditional vaccine development 
approaches are ineffective for HIV-1 because these vaccination protocols rely on CD4+ T 
cells to induce protective immunity. The lack of good experimental models to test the 
efficacy of vaccines generates additional challenges. In the following section, highlights 
of traditional and some unique vaccine approaches against HIV-1 are reviewed.  
1.6.1 Traditional vaccine approaches 
To date, many traditional vaccine strategies, such as live-attenuated viruses and 
inactivated viruses have shown their efficiency in controlling viral diseases such as small 
pox, polio and measles. Initially, the effectiveness of these approaches was evaluated in 
the development of HIV-1 vaccines.  
Many safety concerns were raised against the use of live-attenuated vaccines for 
HIV-1 patients. In the few cases that have been studied, (e.g. chimpanzees with simian 
immunodeficiency virus (SIV)-live-attenuated vaccine and humans with non-pathogenic 
Nef-deleted HIV-1-live-attenuated vaccine) the reversion of non-pathogenic virus to the 
virulent form occurred during later stages of vaccination (95-97). Hence, no further 
investigations have been carried out using this approach of vaccine development for HIV-
1. Inactivated or killed vaccines are safer than live-attenuated vaccines and are efficient 
in controlling disease, such as polio and influenza. However, one SIV-inactivated vaccine 
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study on primates (98) and another HIV-1-inactivated vaccine study on humans  both 
failed to induce protective immunity (99). !
A successful subunit vaccine has been developed for Hepatitis B virus, a chronic 
viral disease that causes T cell exhaustion similar to HIV-1 (100, 101). Therefore, 
significant efforts have been spent on the development of recombinant-HIV-1-subunit 
vaccine involving Gp120 epitopes (102). A monomeric recombinant envelope Gp120 
subunit vaccine was produced and its efficacy was tested in clinical trials. Unfortunately, 
this vaccine approach again failed to confer protection as the induced immune response 
was unable to neutralize the broad range of HIV-1 isolates and/or mutants found within 
both the general populace and infected individuals (103).  
1.6.2 Novel vaccine approaches 
 Novel vaccine approaches using live-vector-based and plasmid DNA vaccines 
are under intense study. In the live-vector-based vaccine approach, HIV-1 genes are 
inserted into the live vectors. These vector-based vaccines were administrated into 
humans and were found to simultaneously induce cellular and humoral immune responses 
to both the parental virus and inserted viral genes. Initially, vaccinia virus was used for 
the development of live-vector-based vaccines for HIV-1. When tested in small 
laboratory animals and primates the vaccine proved effective in stimulating HIV-1-
specific immune responses (104-106).  However, these vaccines were discontinued for 
further testing on humans, as they are replication competent and are therefore 
contraindicated for use in immuno-compromised individuals such as AIDS patients.  
 Subsequently, genetically modified and replication-deficient vaccinia vectors 
have been developed (107). Avian and canarypox viruses belong to the vaccinia virus 
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group.  These two viruses were used in HIV-1 vaccine development, and have been 
shown to be effective against multiple strains of HIV-1 virus in primates (108). Currently, 
the efficiency of vaccinia virus vaccines is being testing in HIV-1 patients. In addition, 
adenovirus (AdV) recombinant serotype-5 and RNA alpha virus vectors have been used 
for HIV-1 vaccine development. These virus-based vaccines demonstrated a strong 
immuno-stimulatory capacity in both small animal and primate models, and are currently 
being assessed for safety and immunogenicity in human patients (109).  
 Currently, numerous vaccines are in clinical trials to identify the most effective 
vaccine for HIV-1 (110). Despite these many efforts, none have proven highly promising. 
This is likely due to the fact that HIV-1-infected individuals are deficient in CD4 T cell 
and DC function.  
1.6.3 Therapeutic vaccine approaches 
 The limitations of HAART and the importance of the continuous presence of 
humoral and cell-mediated immune response in halting HIV-1 replication and disease 
progression have forced immunologists to explore novel therapeutic approaches, 
including novel vaccines. The goal of these vaccines is to be effective in controlling 
disease progression rather than curing disease. Many experimental studies have shown 
the therapeutic role of CD8+ CTLs in controlling established HIV-1 infection. The 
administration of autologous monocyte-derived DCs loaded with immunogenic HIV-1 
peptides to patients resulted in increased HIV-1-specific CD8+ CTLs responses, and 
reduced viremia (111). Schmitz et al. (82) also confirmed the importance of CD8+ T cells 
in controlling SIV infection in macaque monkeys. Similarly, Amara et al. (81) 
demonstrated the ability of recombinant-modified-Ankara-vaccinia vaccine to increase 
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Ag-specific immune response in monkeys using heterologous prime-boost regimens. 
Together, these results suggest the importance of therapeutic vaccines in increasing HIV-
1-specific CD8+ CTL responses, thereby preventing progression of disease by controlling 
viral replication.  
 
1.7 Adenoviral vectors  
AdV-based vectors are widely used in clinical and basic research studies 
worldwide.!AdVs infect the upper respiratory tract. The associated symptoms are similar 
to those of the common cold (influenza infection) (112).  In the laboratory, AdVs infect a 
broad range of cultured mammalian cells, both dividing and non-dividing cells, which 
enables expression of recombinant proteins of interest (113). Currently, AdVs are being 
used for a variety of applications, including vaccine development, gene therapy, and gene 
expression studies. To date, nearly 53 human AdV serotypes have been identified (114). 
A comprehensive knowledge of AdV biology and their unique infectious characteristics 
makes them excellent vectors for transgene expression studies. Human serotypes AdV-2 
and -5 are the more commonly used laboratory recombinant adenoviral strains. These 
recombinant AdVs are highly antigenic in nature, similar to the parental strain (wild-
type), and induce strong cell-mediated immune responses. This strong immune response 
is one of the major limitations of using AdVs for therapeutic purpose, as most people 
have been previously exposed to the virus and neutralize the administrated AdV quickly 
(115, 116).  Hence, efforts are being made to develop vaccines using serotypes of non-
human AdVs, such as bovine AdVs and porcine AdVs. Importantly, AdVs possess the 
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characteristic of efficient cell-infectivity and their capsid can be easily modified to target 
them to particular type of cells.  
1.7.1 AdV structure  
AdVs are non-enveloped icosahedral viruses containing a linear double-stranded 
DNA genome. They have a large (36 kb) genome that encodes three major and three 
minor structural proteins. AdVs contain inverted terminal repeats on both ends of the 
genomic DNA, which assist in initiation of viral replication. The AdV genome is encased 
by the icosahedral capsid proteins, which make up the exterior of the viral particle.  The 
major proteins within the capsid are the hexon, penton and knob fiber proteins (117). 
Adenoviral transcripts are generally classified as early genes (E1, E2, E3 and E4), 
delayed early or intermediate genes (proteins IX and Iva2) and late genes (L1 to L5). The 
early gene products are crucial for replication, host immuno-suppression and inhibition of 
cell apoptosis. Delayed early gene products are involved in encapsidation, transactivation 
of major late promoter and virus packaging.  And, the late gene products are important 
for assembly of virion particles before their release.  
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Figure 1.1 Schematic representation of the AdV genome. The AdV genome encodes 
early genes (E1A, E1B, E2A, E2B, E3 and E4), delayed early genes (IX and Iva2) and 
late genes (L1 to L5), which are flanked by inverted terminal repeats. The AdV genome 
also contains a major late promoter (MLP) and a packaging signal (#). 
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1.7.2 AdV replication 
Unlike retroviruses, which need to integrate into the genome for replication, AdV 
replication is epi-chromosomal. Infection is initiated by attachment of fiber proteins 
present in the capsid onto cell surface receptors. The coxsackie AdV receptor (CAR) is 
the primary cell surface receptor for AdVs (118) present on epithelial cells. DC and 
macrophage express CAR at low levels and secondary AdV receptors such as integrins at 
high levels (119, 120). After attachment, the AdV knob protein interacts with integrin 
molecules present on the cell surface facilitating the process of receptor-mediated 
endocytosis (121). AdV lyses endosomes and escapes into the cytoplasm. Adenoviral 
DNA is then transported into the nucleus (via nuclear pore transportation) for gene 
transcription. Transcription of the genome begins with early gene transcription of E1A, 
followed by transcription of other necessary genes, such as E1, E2, E3 and E4. Early gene 
products alter the cell’s defensive mechanism and metabolism. E1 and E2 gene products 
are involved in arresting cell cycle to favor AdV replication, whereas E3 and E4 gene 
products are involved in viral-DNA replication (122). The delayed early and late gene 
products are involved in AdV packaging and they are important structural proteins. AdV 
uses host RNA polymerase for gene transcription, then mRNA is exported into cytoplasm 
for translation. During translation, synthesis of DNA polymerase for viral DNA 
replication, and structural proteins occur. Finally, viral particle assembly occurs by 
incorporating viral DNA into synthesized viral capsids (immature capsids). Capsids then 
undergo maturation and viral particles are released though cell lysis (123). 
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1.7.3 Amino acid sequence Arg-Gly-Asp (RGD)-modified AdVs  
In the process of cell entry, the fiber proteins of the AdV attach to the CAR 
present on epithelium of upper respiratory tract. CAR is present on epithelial cells as an 
adhesion molecule, acting as a physical barrier to prevent viral infections. AdVs exploit 
adhesion molecules interaction by inhibiting CAR-CAR dimmer formation and forming a 
strong affinity bond between viral fiber protein and the host’s CAR (124). Subsequently, 
the RGD domain of the penton protein is brought into proximity of the cell integrin 
molecule facilitating binding and internalization through receptor-mediated endocytosis.  
These integrin molecules are present on most cells.  It is difficult to achieve efficient 
infection of typical laboratory cell lines since most cells do not express CARs. 
Specifically with respect to HIV-1 research, AdVs do not naturally infect DCs. To enable 
AdVs to infect different cell types, an RGD motif can be genetically introduced directly 
into the viral fiber knob protein. These RGD-modified AdVs are capable of infecting a 
broad range of cells. A similar study by Sas et al. (125) demonstrated that RGD-modified 
AdV can induce of transgene expression in more than 80%  transduced murine bone 
marrow dendritic cells (BMDCs).  
 
1.8 DC vaccines 
1.8.1 DC 
 DCs are present throughout the body, lying in wait to identify foreign entities and 
potential pathogens.  DCs identify pathogens/Ags and transport them from the periphery 
to lymphoid organs. They also are a key component required to enable transition from the 
innate to the adaptive immune responses. Therefore, DCs are often referred to as 
! #"!
“professional” APCs or “sentinels”.  DCs play a crucial role in identifying invading 
pathogens (danger signals) and sensitizing Ag-specific T cells.  They have the capability 
to activate or inhibit Ag-specific immune responses. Immature DCs internalize invading 
pathogens, viruses, bacteria, and apoptotic bodies through receptor-mediated endocytosis 
and phagocytosis via toll like receptors or C-type lectins.  Upon exposure to certain 
stimulatory microbial products (e.g. lipopolysaccharides, CpG oligonucleotides), and 
inflammatory cytokines (TNF!, IL-1), phagocytosis of the foreign entity occurs, 
followed by formation of lysosomes, maturation and presentation of the microbial 
peptides for T and B cell activation (126). Some pathogens, such as Dengue virus and 
HIV-1, are able to exist within the lysosomal compartment without being processed for 
Ag presentation. Transfer of these unprocessed form of virus to T cells during the process 
of Ag-presentation enhances transinfection (37, 127).  
 During Ag-presentation, DCs present antigenic peptides on MHC class-I and -II 
molecules through which (signal I) Ag-specific CD8+ and CD4+ T cells are activated, 
respectively.  DCs also provide co-stimulatory (signal 2) and cytokine (signal 3) signals. 
In the early events of T or B cell stimulation, the activated DCs move to lymphoid tissues 
to stimulate the adaptive immune response (128). Apoptotic body proteins, such as heat 
shock proteins and beta defensins, are also known to induce DC maturation. Mature DCs 
express high levels of co-stimulatory molecules, such as CD80, CD86, peptide MHC 
class-I and -II complexes and adhesion molecules. In addition, mature DCs exhibit 
reduced expression of endocytic or phagocytic receptors, and increased secretion of IL-12 
and IL-23 cytokines, which are crucial for T cell activation.  
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1.8.2 DCs in immunotherapy 
  At present, DCs, specifically monocyte-derived DCs, are being used in 
immunotherapy to stimulate tumor- or microbial Ag-specific CD8+ CTL responses. A 
study on the treatment of melanoma in humans has demonstrated that adoptive transfer of 
in vitro-proliferated monocyte-derived DCs loaded with tumor peptides was able to 
induce strong tumor-specific immune responses (129). Similarly, in phase-I clinical trials 
of prostate cancer, DCs transfected with DNA encoding cancer-specific Ags were shown 
to stimulate tumor-specific T cell responses (130). In contrast, in the treatment of 
allergies and autoimmune disorders, tolerogenic DCs were able to induce tolerance by 
expanding specific regulatory T cells or inactivating already expanded T cells (131).  
The whole-cell DC-based tumor vaccines have been used to treat cancer (132, 
133) using tumor-specific Ag-expressing adenoviral vectors to transduce DCs. This helps 
to overcome the problem of natural long-lasting immunity to AdVs in previously 
sensitized patients that prevents AdV immunizations. Stimulation of DCs via AdV 
transduction could be more beneficial than stimulation using purified antigenic 
molecules, since AdV infection results in a strong signal to toll like receptors, which is 
required for maturation of DCs (133, 134). DC vaccines have been shown to be able to 
break disease-associated tolerance and have subsequently proven beneficial to patients 
with cancer or chronic diseases. Compared to other available cancer vaccines, initial 
clinical trials show that DC vaccines are safer to use (135). However, many other factors 
need to be evaluated, such as dose, route of administration, and method of maturation, 
activation, and Ag-loading. Understanding these factors may result in further 
improvement. With respect to HIV treatment, DC-based vaccines may not be as 
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promising as they will need to overcome the requirement of CD4-help for CD8+ T cell 
activation.  
 
1.9 Exosome (EXO)-derived vaccines 
1.9.1 EXOs 
EXOs are one of many examples of small secretory vesicles present in cell culture 
medium. EXOs are present in endosomes and are released into the culture medium when 
the endosome fuses with the cell membrane.   
To date, different types of secretory membrane vesicles have been isolated and 
characterized from the mammalian cell-culture supernatants. Based on physiochemical 
characteristics, such as size, density, appearance under electron microscope, intracellular 
origin or protein composition, secretory membrane vesicles are classified into many 
types. The most biologically important secretory vesicles studied include EXOs, EXO-
like vesicles, microvesicles, ectosomes, membrane particles and apoptotic bodies (136). 
EXOs have been extensively studied and characterized especially in the immunological 
context due to their immuno-stimulatory property (137).  
EXOs are small lipid bilayer vesicles of 50 to 100 nm in diameter and can be 
isolated from cell-culture supernatants. EXOs are spherical in shape, however, they often 
appear “cup” or “saucer” shaped in electron micrographs (138). EXOs play a major role 
in transferring membrane-associated molecules from one cell to other. Many studies have 
demonstrated the presence of multiple receptors and ligands on the surface of EXOs, 
which allow them to interact with different cells (139).  
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The protein composition of EXOs provides information regarding their pathway 
of origin. Many studies have confirmed that proteins related to mitochondria, golgi 
complex, endoplasmic reticulum or nucleus are not observed in EXO. However, most of 
the proteins existing in EXOs are found to be present in the cytoplasm and plasma 
membrane. Flow cytometry and western blot analysis showed that EXOs contain 
important trans-membrane proteins, where these proteins are not necessarily derived from 
plasma membrane (140), and cytosolic proteins, such as annexin II, and TSG101. EXOs 
contain proteins mainly present in endocytic pathways, indicating that they are endocytic 
in origin (141). Lysosomal or endosomal proteins, such as lysosomal-associated 
membrane proteins (LAMPs), are observed in EXOs and are often found in DC- and B 
cell-released EXOs (138, 142). Enzymes involved in metabolism and various proteins 
involved in cell signaling are present in EXOs. In addition, tetraspanin family proteins, 
such as CD63, CD81 and CD82, are also abundant in EXOs.  
1.9.2 DC-released EXOs in vaccination  
Among the different types of EXOs, DC-released EXOs have attracted greater 
attention from immunologists since they possess immuno-stimulatory functions. Unlike B 
cell-released EXOs, DC-released EXOs are heterogeneous in size (143). One of the 
remarkable features of DC-secreted EXOs is their composition; they consists of Ag-
presenting machinery such as MHC-I and -II molecules, co-stimulatory molecules such 
as CD80 and CD86, and adhesion molecules such as CD11c and CD54, which are 
collectively required to induce immune responses (144, 145).  
Numerous studies have shown the functional importance of EXOs derived from 
different cell types such as DCs, T cells, B cells, platelets, mastocytes, fibroblasts and 
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tumor cells, both in vitro and in vivo in different animal models. In vitro studies 
confirmed that EXOs alone, unlike DCs, are unable to stimulate T cell responses (138). 
EXOs released from DCs or tumor cells are involved in transferring Ag-specific MHC 
complexes and immuno-stimulatory molecules to mature DCs, which in turn gain the 
ability to stimulate Ag-specific T cell responses. For the first time, Zitvgel et al. (138) 
showed that immunization with DC-released EXOs completely eradicated well-
established tumors in murine model. Raposo et al. (143) showed that EXOs derived from 
B cells transduced with Epstein-Barr virus were able to stimulate Ag-specific CD4+ T 
cells in vivo in humans. In addition, EXOs secreted by tumor cells have been shown to 
play a major role in cross presentation of tumor Ags to mature DCs (142, 146). EXOs 
released from tumor cells are known to express tumor-specific Ags on MHC-I molecules. 
These molecules can be used as an Ag source in cancer immunotherapy by loading them 
onto DCs to induce strong tumor-specific CD8+ CTLs and memory response (138). Many 
studies have also shown that tumor-specific EXOs can successfully cause regression of 
tumors in skin and lymph nodes (147, 148). As part of a phase-I clinical trial in Institute 
Gustave Roussy and institute Curie, France, DC-derived EXOs are being used to treat 
different metastatic malignancies in humans (147).   
Recently, the concept of using EXO-loaded T cell vaccines in immunotherapy has 
gained more attention. It has been demonstrated that EXO-based T cell vaccines can 
stimulate strong Ag-specific CD8+ CTL responses and provide anti-tumor immunity 
(149). Hao et al. (150, 151) also demonstrated that CD4+ T cells, which have acquired 
exosomal molecules, are more efficient than mature DCs in stimulating Ag-specific 
effector CTLs, memory response, and anti-tumor immunity.  
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Regardless of whether EXOs have in vivo or in vitro immuno-stimulatory effects, 
a full understanding of EXO function and physiological relevance is still elusive. 
Furthermore, the mechanisms by which EXOs induce immune stimulation are not well 
understood. 
 
1.10 EXO-targeted active CD4+ T cell (CD4+aTexo) vaccine 
Transfer of membrane molecules has been reported to occur between different 
types of immune cells including DCs (10), T cells (152), B cells, NK cells (153), 
basophiles (10) and macrophages (153, 154). Several possible mechanisms have been 
proposed to explain intercellular membrane molecular transfer. Among these, the two 
most important mechanisms of relevance to immunology are: 1) immunological synapse 
formation - between DCs and T cells facilitating T cell stimulation (155); and 2) DC-
released EXOs.  DC-released EXOs, expressing MHC-I & -II, and co-stimulatory 
molecules, modulate immune responses when they transfer to other immune cells (156, 
157).  
The formation of an immunological synapse between APCs and Ag-specific 
CD4+ T cell is a key event for activation of T cells (158, 159). It has been reported that, 
during formation of the immunological synapse, APC surface molecules get transferred 
to T helper cells through the process of internalization and recycling pathways (160, 161). 
Based on this principle, Xiang et al. (162) proposed a new dynamic model of Ag-
presentation. According to this model, CD4+ T cells stimulated with ovalbumin (OVA)-
specific DCs (DCOVA) acquire Ag-presenting machinery, such as peptide major histo-
compatibility complex (pMHC)-I and –II complexes, and co-stimulatory molecules, 
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CD80 or CD86, and behave like APCs (called CD4+ T helper Ag-presenting cells (Th-
APCs)) (163). These Th-APCs are known to stimulate naïve Ag-specific CD8+ T cells to 
become effector and memory CD8+ T cells, thereby providing anti-tumor immunity to the 
host (162). Subsequently, Umeshappa et al. (164) demonstrated that Th-APCs have fewer 
pMHC-I complexes compared to DCOVA. The Th-APCs were able to induce central 
memory CTL development whereas DCOVA were able to stimulate effector memory CTL 
development. In addition, it was shown that the Th-APCs’ stimulatory effect is mainly 
mediated through acquired pMHC-I complex (signal-1), CD40L-co-stimulation (signal-2) 
and IL-2 cytokine secretion (signal-3) (165).     
Based upon this new concept of Th-APCs, which induce immune responses via 
acquired pMHC-I and co-stimulatory molecules (162, 165), Hao et al. (150) 
demonstrated the development of a novel EXO-targeted T cell vaccine using polyclonally 
actived CD4+ T cells co-cultured with EXOs derived from Ag-stimulated DC.  In this test 
case, the Ag OVA was used. The CD4+aTexo cells/vaccine efficiently stimulated an 
OVA-specific CD8+ T cell response and elicited immunity to tumor lines bearing the 
OVA Ag. It has been shown that CD4+aTexo vaccines can induce stronger immune 
responses than OVA-specific EXO (EXOOVA) and DCOVA alone (150). Interestingly, the 
stimulation of OVA-specific CD8+ T cells by CD4+aTexo vaccine was found to be CD4-
independent, but relied on acquired pMHC-I complex and co-stimulatory molecules 
(150). Furthermore, it has been found that CD4+aTexo vaccine has the ability to stimulate 
CD8+ central memory CTL responses in the absence of CD4+ Th cells, but in the 
presence of CD25+ T regulatory cells (151), suggesting their potential application in HIV-
1 vaccine development. Unfortunately, CD4+ T cells are targets for HIV-1, and it is likely 
! #)!
that this vaccine will fail to induce efficacious results upon vaccination in HIV-1 patients.  
Therefore, this thesis focuses on whether a similar result can be achieved through 
activating CD8+ T cells using EXOOVA and HIV-1-specific EXOs. 
 !!!!!!!!!!!!!!!!!!!
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CHAPTER 2 
HYPOTHESIS 
 CD4+ T cell deficiency is the hallmark of HIV-1 infection and stimulation of HIV-
1-specific CD8+ T cell responses in this CD4-deficient environment is a major scientific 
challenge. Existing vaccination approaches, using subunit, recombinant or killed 
strategies, rely on functional CD4+ T cells to induce protective immune responses. Anti-
retroviral therapies targeting DNA replication decrease HIV-1-related morbidity and 
mortality (7). However, these treatments are associated with many disadvantages 
including long-term toxicity, high cost, development of drug resistance, and failure to 
clear residual virus completely. Hence, there is a great need to develop alternate methods 
to stimulate immune response.  Ideally these alternate methods would stimulate CD4-
independent CD8+ T cell responses. 
 Previously, it was demonstrated that non-specific CD4+ aT cells take up OVA-
specific EXOs. These cells are the basis behind what has been termed the CD4+aTexo 
vaccine (150). This vaccine was able to stimulate Ag-specific CTL responses 
independent of CD4+ T cell help and able to induce both effector and memory CD8+ T 
cells. The vaccine was also able to protect mice exposed to lethal doses of Ag-specific 
tumor cells. It was reported that CD4+aTexo vaccine’s stimulatory effect occurs 
independent of CD4+ T cell help and was mediated through acquired pMHC-I complex, 
CD40L and CD80 co-stimulations, and IL-2 secretion (150, 151). This type of immuno-
stimulation, independent of CD4+ T cell, would appear to have promise in the 
development of a HIV-1 vaccine. 
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 CD8+ T cells share many features of CD4+ T cells.  If EXO targeted active CD8+ 
T cells (CD8+aTexo) were able to induce an immune response in a similar manner as the 
CD4+aTexo vaccine, then this technique could be an ideal approach in the control of 
HIV/AIDS.  This thesis first tests the hypothesis that CD8+ T cells can be stimulated in an 
Ag-specific manner using OVA-activated DC-derived EXOs in CD8+aTexo vaccine 
preparation.  Secondly, it was hypothesized that the use of CD8+aTexo could induce 
HIV-1-Gp120-specific CD8+ T cell responses. Gp120 contains many conserved epitopes 
for CD8+ T cells to induce effective CD8+ CTL responses. CTLs specific to an epitope of 
Gp120 are cross-reactive with some of other Gp120-specific CTL epitopes slightly 
modified in their amino acid sequence. Therefore, if proven efficacious, Gp120-specific 
CD8+aTexo (Gp120-aTexo) vaccine could induce efficient cross-reactive CD8+ T cell 
responses that can target a broad-range of HIV-1 isolates. 
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CHAPTER 3 
OBJECTIVES 
 The proposed research objectives were as follows. 
 My first objective was to develop an OVA-specific CD8+aTexo (OVA-aTexo) 
vaccine and test its stimulatory capacity. This involved development of an OVA-aTexo 
vaccine and testing its immuno-stimulatory potential in wild-type mice. OVA-aTexo 
vaccine was also developed, which was selectively deficient in pMHC-1 and CD40L 
molecules. Testing specific molecule deficient OVA-aTexo vaccine stimulatory function 
in wild-type mice was performed to understand molecular mechanism of immuno-
stimulation. OVA-aTexo vaccine immuno-stimulation was also tested in IL-2R!-/- mice 
to analyze the involvement of IL-2 signaling. 
 My second objective was development of a Gp120-aTexo vaccine and testing its 
stimulatory capacity in wild-type and transgenic A2-Kb mice. Here, I first transfected 
dendritic cell 2.4 (DC2.4) and BL6-10 cell lines with Gp120 or/and A2-Kb, and 
constructed an AdV vector to express Gp120 protein. I then developed Gp120-aTexo 
vaccine and tested its immuno-stimulatory capacity in wild-type and A2-Kb mice using a 
tumor challenge study. 
 My third objective was to assess Gp120-aTexo vaccine’s immunotherapeutic 
efficacy in A2-Kb mice by employing a tumor challenge study. 
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CHAPTER 4 
MATERIALS AND METHODS 
 The source of chemicals, reagents and media used in this study are given in Table 
4.1. Composition of solutions, buffers and media used are given in Table 4.2. Abs used 
for the study are listed in Table 4.3. 
Table 4.1 List of chemicals and reagents 
Reagents Suppliers 
1 kb ladder Invitrogen 
Acrylamide:bisacrylamide Bio-Rad 
Agar Invitrogen 
Agarose Invitrogen 
Alkaline phosphatase New England Biolab 
Ammonium Chloride EM Sciences 
Ammonium persulfate Gibco 
Ampicillin Sigma 
Bacto-tryptone BD Pharmingen 
Blocking buffer LI-COR Odyssey 
Bovine serum albumin Sigma 
Calcium chloride Sigma 
Cesium chloride Sigma 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) Molecular Probes 
Chloroform EM Sciences 
Dulbecco’s modified eagle’s medium (DMEM) Gibco 
Dimethyl sulfoxide Sigma 
dNTP mix (dATP, dCTP, dGTP, dTTP) Invitrogen 
Eagle’s minimum essential medium (EMEM) Gibco 
Ethanol EM Sciences 
Ethidium bromide  Sigma 
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Reagents Suppliers 
Ethylenediamine tetra acetic acid (EDTA) Sigma 
Fetal bovine serum (FBS) Cyclone 
Histopaque-1077 Sigma 
Formalin EM Sciences 
Gentamicin reagent Gibco 
Glutaraldehyde Sigma 
Glycerol BDH Inc 
Glycine EM Sciences 
Granulocyte macrophage-colony stimulating factor (GM-CSF) R & D Systems 
Hydrochloric acid EM Sciences 
IL-2 Peprotech 
IL-4 R & D Systems 
Isopropanol Gibco 
Kanamycin EM Sciences 
LS column Miltenyi Biotec 
Magnesium chloride Sigma 
Methanol EM Sciences 
Mouse CD8 (Ly-2) paramagnetic beads Miltenyi Biotec 
Phenol  EM Sciences 
Pre-stain molecular weight protein marker Bio-Rad 
Proteinase-K Invitrogen 
RNAse Amersham Biosciences 
Roswell park memorial institute (RPMI)-1640 Gibco 
Sodium dodecyl sulfate (SDS) Sigma/ Bio-Rad 
Sodium acetate BDH Inc 
Sodium azide Sigma 
Sodium hydroxide EM Sciences 
Streptomycin Sigma 
Sucrose BDH Inc 
Sulfuric Acid BDN Inc 
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Reagents Suppliers 
T4 DNA ligase New England Biolabs 
Taq DNA polymerase Invitrogen 
Tetramethylethylenediamine Gibco 
Tris EM Science 
Trypan blue stain Gibco 
Trypsin/EDTA Gibco 
Tween-20 Bio-Rad 
Yeast extract Gibco 
Alpha-minimum essential medium  Gibco 
"-mercaptoethanol Bio-Rad 
$DNA/HindIII marker Invitrogen 
%X174/HaeIII fragment marker Invitrogen 
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Table 4.2 Compositions of the solutions, buffers and media 
Solutions, Buffers 
and Medium 
Composition 
1M CaCl2 7.35 g of CaCl2 in 50 ml of water 
6X DNA loading 
buffer 
0.25% (w/v) bromophenol blue, 0.25% (v/v) xylene cyanol, 
40% (w/v) sucrose in 10 ml of water. 
Citric saline 10%  (w/v) KCl and 4.4% (w/v) sodium citrate  
Luria-Bertani (LB) 
agar 
1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 1% 
(w/v) NaCl and 1% (w/v) agar 
LB broth 1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 1% 
(w/v) NaCl, pH 7.0 
Lysis buffer solution 0.2 M NaOH, 1% (w/v) SDS in 100 ml of water 
Phosphate-buffered 
saline (PBS) 
140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.2 
Tween-PBS 0.05% (v/v) Tween-20 in PBS 
Precipitate solution 3 M CH3CO2K, 11.5% (v/v) glacial acetic acid in 100 ml of 
water. 
Protein sample buffer 125 mM tris pH 6.8, 4% (w/v) SDS, 10% (v/v) glycerol, 
0.006% (w/v) bromophenol blue, 1.8% (v/v) &-mercaptoethanol 
Resuspension buffer Glucose 50 mM, EDTA 10 mM, tris 25 mM in 100 ml of water 
1X Running Buffer 3.5 g Tris, 14.45 g glycine, 0.5 g SDS and water to 1 L 
SOC medium 2% (w/v) Bactro-tryptone, 0.5% (w/v) Bacto-yeast extract, 
0.05% (w/v) NaCl, 20 mM glucose, 2.5 mM KCl, 10 mM 
MgCl2, pH 7.0 
Tris-acetate EDTA 
buffer 
24% (w/v) tris, 5.7% (v/v) glacial acetic acid, 10% (w/v) 
EDTA, pH 8.0 
Transfer buffer Tris 3.03 g, Glycine 14.4 g, methanol 200 ml and water to 1 L 
Tri-ammonium 
Chloride lysis buffer 
8.26 g of NH4Cl, 1 g of KHCO3, 0.037 g EDTA in 1 L of water. 
Mix well and autoclave before use. 
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Table 4.3 List of fluorescein isothiocyanate (FITC), phycoerythrin (PE), energy 
coupled dye (ECD) or biotin-conjugated Abs used in the study  
Antibodies Clone number Suppliers 
Anti-H2-Kb/OVA1 (pMHC-I)  eBiosciences 
Anti-mouse CD11c-FITC HL3 BD Pharmingen 
Anti-mouse CD25-FITC 7D4 BD Pharmingen 
Anti-mouse CD40-FITC HM40-3 BD Pharmingen 
Anti-mouse CD54-FITC 3E2 BD Pharmingen 
Anti-mouse CD80-FITC 16-10A1 BD Pharmingen 
Anti-mouse CD86-FITC GL-1 BD Pharmingen 
Anti-mouse CD8-FITC CT-CD8! Beckman Coulter 
Anti-mouse H2-Kb  -FITC AF6-88.5 BD Pharmingen 
Anti-mouse Iab    -FITC AF6-120.1 BD Pharmingen 
Anti HLA-A2 BB7.2 Santa Cruz Biotechnology  
Anti-mouse CD40L MR1 Biolegend 
Anti-mouse CD62L MEL-14 BD Pharmingen 
Anti-mouse CD69 H1.2F3 BD Pharmingen 
Anti-mouse CD44 IM7 BD Pharmingen 
Anti-mouse CCR7 4B12 eBiosciences 
Anti-mouse IL-7R! A7R34 eBiosciences 
Avidin-IRDye700CW  LI-COR Odyssey 
Anti-rat IRDyeRCW800  LI-COR Odyssey 
Anti-mose-IRDyeRCW700  LI-COR Odyssey 
Anti-Calnexin  Cell-Signaling technology 
Biotinylated goat anti-HIV-Gp120  Cederlane 
Anti-LAMP-1  Santa-Cruz Biotechnology 
Streptavidin-FITC  BD Pharmingen 
Streptavidin-PE texas Red  BD Pharmingen 
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4.1 Cell lines 
BL6-10 cells are skin melanoma tumor cells of C57BL/6 mouse origin. BL6-10 
and BL6-10OVA tumor cells were cultured in alpha-minimum essential medium. DC2.4 is 
a DC cell line of C57BL/6 mouse origin, and was kindly provided by Dr. K L Rock, 
Dana Farber Cancer Research unit, Boston, MA. DC2.4 cells were cultured in DMEM.   
Human embryonic kidney cells (HEK-293) express early region-1 (E1) product of 
AdV, which helps the growth and amplification of replication deficient AdV. These cells 
were purchased from the Microbix, Toronto, ON, and cultured in EMEM. All culture 
media were supplemented with 10% (v/v) FBS and 30 µg/ml gentamicin reagent. 
Trypsin/EDTA solution and 1X citric saline solution were used for BL610 and HEK-293 
cell passage, respectively. Cells were cultured in a humidified incubator at 37oC with 5% 
CO2 saturation. Viable cells were counted using Trypan blue stain using a 
haemocytometer. 
 
4.2 Bacterial cells  
 Escherichia coli, DH5" strain (New England Biolabs), was routinely used for 
expression-vector propagation. E. coli, BJ5183 strain (Stratagene), was used for the 
homologous recombination in AdV vector construction. Both cells were grown in LB a 
broth at 37oC on a shaker. Medium was supplemented with selective antibiotic, ampicillin 
(100 µg/ml) or kanamycin (50 µg/ml), depending on the expression vector’s resistance 
gene. After transformation, transformed bacterial cells were selected by plating them on 
selective LB-agar plates containing appropriate selective antibiotics, and plates were 
incubated overnight at 37oC. 
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4.3 Animals 
 Wild-type (C57BL/6) female mice with H2-Kb background, and transgenic A2-Kb 
mice were obtained from the Animal Resource Centre, University of Saskatchewan and 
Charles River Laboratories, Canada, respectively. CD40L, Kb and IL-2R" gene knockout 
(KO) mice on C57BL/6 background were purchased from Jackson Laboratory, USA. 
Mice were 4-6 weeks old at initiation of the experiments and were housed in the animal 
facility at Saskatoon Cancer Center or in the Health Science Building, Laboratory Animal 
Service Unit. Animal protocols and procedures used in this study were approved by the 
University Committee on Animal Care and Supply in accordance with the guidelines of 
the Canadian Council for Animal Care.  
 
4.4 Peptides  
 OVA-I peptide, SIINFEKL, was obtained from the Peptide Core Synthesis Facility, 
University of Calgary, AB, Canada. This peptide spans between 257-264 of the OVA 
protein (166). Gp120 peptide, KLTPLCVTL, was obtained from the GenScript, USA Inc, 
Custom service peptide facility and the peptide spans between 121-129 of the Gp120 
protein (167, 168). Both peptides were purified by high-performance liquid 
chromatography (HPLC), which yielded >95% purity.  
 
4.5 General molecular biology techniques  
General molecular biology techniques used in this study were based on the 
protocols described in Molecular Cloning, a Laboratory Manual by Sambrook et al. (215) 
and Sambrook and Russel (216) with few modifications.  
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4.5.1 Restriction enzyme digestion 
The restriction enzymes used in this study were purchased from New England 
Biolabs. DNA digestions were performed according to the manufacturer guidelines. 
Briefly, around 1 µg of DNA was digested using at least 1 unit of specific restriction 
enzyme in 1X recommended optimal buffer in the presence or absence of bovine serum 
albumin for 1 hr at 37oC.  
4.5.2 Agarose gel electrophoresis 
Agarose gels were prepared in varying concentration, from 0.7% (w/v) to 2% 
(w/v), in tris-acetate EDTA buffer, depending on the size of the DNA band to be 
visualized. Concentration of 1 µg/ml Ethidium bromide was used in the gel to stain DNA. 
Samples were mixed with loading buffer and loaded on the gel along with DNA markers, 
$DNA/Hind III, %X174/Hae III or a 1 kb ladder from New England Biolabs. For optimal 
resolution, gels were run between 90 to 110 volts in tris-acetate EDTA buffer for varying 
times, and then bands were visualized under UV trans-illuminator gel documentation 
system (Bio-Rad). 
4.5.3 Purification of linear DNA fragments  
 For further downstream applications, such as cloning and transfection, linear DNA 
fragments were purified from agarose gel using a Min-gel elution kit (Qiagen). The 
method was followed as per the procedure provided by manufacturer. Typically, DNA 
was eluted in 20 µl of sterile water to facilitate the subsequent ligation or transfection 
procedures. 
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4.5.4 Competent cell preparation and transformation 
4.5.4.1 Chemical competent cell preparation and transformation  
Chemical competent cells of E coli strain DH5", recombination-deficient bacteria, 
were prepared according to the method in Sambrook et al. (215) with few modifications. 
In brief, 100 ml of 16 hr cultured bacterial cells of OD between 0.4-0.6 at 600 nm were 
pelleted. Cell were washed twice with 10 ml of chilled 50 mM CaCl2 and re-suspended in 
1 ml of CaCl2 solution containing 15% (v/v) glycerol.  
For transformation, 100 'l of competent cells were incubated with 10-20 ng of 
plasmid DNA on ice for 30 min. Cells were heat-shocked by quickly placing into a 42oC 
water bath for 40 sec without shaking. The samples were then placed on ice for 2 min. 
Pre-warmed super optimal broth (SOC) was added to the samples and incubated for 2 hr 
at 37oC to allow cell recovery. Finally, the cells were plated on selective antibiotic LB 
agar plates and incubated overnight at 37oC. 
4.5.4.2 Electrocompetent cell preparation and transformation 
This method was adopted from Sambrook and Russell et al. (216). For 
electrocompetent cells preparation, E coli, BJ5183 bacterial cells were grown for 16 hr in 
LB broth containing selective antibiotic. The cells were then sub-cultured into fresh 
medium and grown to reach mid log phase (OD600 0.4-0.6). The culture was chilled on 
ice for 30 min, then spun at 1000 X g in a JA-20 rotor (Beckman Coulter). Finally, the 
cells were washed 2-3 times in cold water, re-suspended in 10% (v/v) glycerol in water, 
then stored at -80oC until use.  
Electrotransformation was performed to transfer AdV vector into bacteria, 
BJ5183, which contained of pAdEasy-1 AdV backbone vector. Briefly, electrocompetent 
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cells were transferred into pre-chilled electroporation cuvettes (Bio-Rad) and incubated 
with linearized plasmid DNA for 5 min. Electroporation was achieved by applying a 
200( (ohms), 2.5 kV and 25 µFD electric field in a Gene Pulser (Bio-Rad). Immediately 
after electric shock, pre-warmed SOC medium was added to the samples, which were 
then incubated for 1 hr at 37oC to allow cell recovery. Finally, the cells were plated on 
selective antibiotic LB agar plates and incubated overnight at 37oC. 
4.5.5 Isolation of plasmid DNA  
4.5.5.1 Small scale purification  
To isolate plasmids in small scale, the Mini-prep (Qiagen) purification kit was 
used. Generally, bacterial colonies were selected from overnight-incubated plates and 
cultured for 12-14 hr in 2 ml LB medium containing selective antibiotic. Purification was 
performed according to the manufacturer’s protocol. Finally, purified plasmid DNA was 
quantified in a Nanodrop (Thermo-Scientific) instrument. 
4.5.5.2 Large scale purification  
Transfection of HEK-293 cells to generate AdV requires an AdV vector in large 
quantity. In addition, the recombinant AdV vectors are large in size, more than 38 kb, 
hence, they can shear in miniprep column purification. Therefore, plasmids were isolated 
by a traditional alkaline lysis method. In brief, 10 ml of overnight grown cultures were 
pelleted and cells were re-suspended in 1 ml of Resuspension Buffer by vortexing for 3 
min. One ml of freshly prepared Lysis Buffer was added, mixed gently and kept at room 
temperature for 5 min. One ml of precipitate solution was added to the mixture and the 
tubes were inverted 5-6 times to mix. The samples were centrifuged at 12,000 rpm 
(17418 X g) for 20 min in a JA-20 rotor (Beckman Coulter) at 4o C and the supernatant 
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was transferred into fresh tubes. Plasmid DNA was precipitated using 
phenol:chloroform:water and iso-propanol. The DNA pellet was washed twice in 70% 
ethanol, finally dissolved in sterile water. 
4.5.6 RNA isolation ! RNA was isolated from transfected and non-transfected cells using a RNeasy mini 
kit (Qiagen) by following the manufacturer’s guidelines. Sample concentration and purity 
was determined using a Nanodrop instrument. After purification, samples were used 
immediately for cDNA preparation (see Section 4.5.9). 
4.5.7 DNA ligation 
DNA ligation was performed using T4 DNA ligase in supplied ligation buffer. 
Typically, a 20 µl ligation reaction consists of 50 ng of vector DNA, at least 150 ng of 
purified insert DNA with 1-5 units of T4 DNA ligase in 1X ligation buffer. Ligation 
reactions were performed overnight at room temperature.  
 4.5.8 DNA sequencing 
 Automated dideoxy sequencing was performed at the sequencing facilities located 
in Plant Biotechnology Institute of the National Research Council of Canada in 
Saskatoon, Canada. 
4.5.9 cDNA synthesis 
 Approximately 2 to 5 'g of isolated total RNA of each sample was used to prepare 
cDNA using a Superscript-II Reverse transcriptase kit (Invitrogen) by following 
manufacture’s instructions. Briefly, in 12 µl reaction volume, 2 to 5 'g of total RNA and 
oligo (dt) primers were boiled at 65oC for 5 min and then chilled on ice. To this reaction 
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mixture, first-strand enzyme buffer was added and incubated at 42oC for 2 min. 
SuperScript-Reverse transcriptase enzyme and water were added to obtain a final volume 
of 20 µl. The reaction mixture was incubated at 42oC for 50 min, then incubated at 70oC 
for 15 min to terminate the reaction.  Prepared cDNA samples were stored at -80oC until 
further use.!
4.5.10 Polymerase chain reaction (PCR) 
 PCR was carried out using a thermal cycler (Perkin Elmer Gene Amp-PCR system) 
and the New England Biolabs high fidelity PCR kit. A typical 50 µl reaction mixture 
consisted of 0.5 ng of template DNA, 10 mM each of dNTP, 5 µM of each primer, 10X 
PCR buffer, high fidelity polymerase and ultra pure water. PCR was performed by initial 
denaturation of samples at 98.4oC for 45 sec, followed by 30 cycles of 10 sec 
denaturation at 98oC, 30 sec annealing at 62oC, 40 sec extension, and 10 min of final 
extension at 72oC. An aliquot of each sample were subjected to electrophoresis on 1% 
(w/v) agarose gel for visualization of the PCR product. For gene amplification, the 
Gp120-Forward, 5’ ATCTATGGTACCTCTAGAGCCCCTCCATG 3’ and GP120-
Reverse, 5’- AGCTGTAAGCTTGGATCCTTAGCGCTTCTC 3’ primers, which include 
Kpn I and Hind III restriction sites, respectively, were used to facilitate directional 
cloning of PCR product into the pShuttleCMV AdV entry vector. 
4.5.11 Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR)!
Isolated RNA samples were subjected to quantitative RT-PCR using a SYBR 
green Q-PCR master mix (Applied-Biosystems) according to the manufacturer’s 
instructions. Briefly, 25 µl reaction mixture was consisting of 20 ng of cDNA, 50 nM of 
each primer and 1X PCR master mix. To quantify Gp120 transcripts, a series of samples 
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containing 0.2 ng to 0.2 µg of pConBGp120-opt were used to develop a standard curve. 
To determine relative expression of Gp120, the concentration of Gp120 transcripts in 
each sample was normalized to relative expression of &-actin as cycle threshold. The 
samples were amplified in a real time thermo cycler (Applied Biosystems) and data were 
analyzed in the thermo cycler-associated software. The sequences of primers used in this 
analysis include: &-actin F; TTCGTTGCCGGTCCACA, &-actin R; 
ACCAGCGCAGCGATATCG, Gp120 F: TGATGCACTCCTTCAACTGC, and Gp120 
R: TCCTGCCACATGTTGATGAT. 
 
4.6 Expression vectors 
4.6.1 pConBGp120-opt 
pConBGp120-opt expression vector was originally obtained from the National 
Institute of Health. This expression vector has the full-length gene of HIV-I envelope 
protein Gp120. Gene-Gp120 is present between Xba I and BamH I restriction sites. 
pConBGp120 has a neomycin gene, which enables selection of transfected cells.   
4.6.2 pcDNA3.1Hygro-Gp120 
Vector pConBGp120-opt was digested with Xba I and BamH I restriction 
enzymes, which liberated the 1.5 kb full-length Gp120 gene. This liberated DNA 
fragment was ligated into the pcDNA3.1Hygro (Invitrogen) expression vector on same 
restriction sites to get pcDNA3.1Hygro-Gp120 expression vector. This vector has a 
hygromycin drug resistance gene to facilitate selection of stable cell transfectants.  
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4.6.3 pmax-green fluorescent protein (GFP) 
The pmax-GFP expression vector provided with the Amaxon cell line 
Nucleofector-V transfection kit was used as a positive control to monitor transfection 
efficiency. This vector encodes GFP; therefore, GFP-expressing cells after transfection 
can be easily identified by fluorescence microscopy or flow cytometry analysis. 
 
4.7 AdV-Gp120 production  
AdV was generated using an AdEasy-1 adenoviral vector system that utilizes E. 
coli homologous recombination. Parental vectors used in AdV construction, 
pShuttleCMV and pAdEasy-1, were obtained from Dr. Lixin Zhang, John Hopkins and 
Stratagene, respectively. 
4.7.1 Generation of pAdEasy vector expressing Gp120 
Gp120 gene was amplified from expression vector, pConBGp120-opt, by PCR 
using full-length gene-specific primers, which include Kpn I and Hind III restriction sites 
to facilitate directional cloning. Amplified fragments were purified, digested using Kpn-I 
and Hind-III restriction enzymes, and cloned into pShuttleCMV to get pShuttleCMV-
Gp120 vector. Orientation of the gene insertion was confirmed by restriction digestion 
analysis, and sequenced for mutations. pShuttleCMV-Gp120 vector was linearized using 
Pme-I restriction enzyme, then treated with alkaline phosphatase. Approximately, 1 µg of 
Pme-I linearized pShuttleCMV-Gp120 was used to transform electrocompetent AdEasier 
cells, E coli BJ5183, which contain the RGD-motif modified AdV backbone plasmid, 
pAdEasy-RGD. Recombination between AdV backbone vector (pAdEasy-RGD) and 
entry vector (pShuttleCMV-Gp120) leads to the generation of recombinant adenoviral 
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vector (pAdEasy-Gp120), which is used to generate AdV in HEK-293 cells.  Electro-
transformed cells were plated on selective kanamycin (100 µg/ml) LB agar plates and 
incubated overnight at 37oC. Around 40 very small colonies were picked up to perform 
Mini-preps. The recombinants were screened using Pac-I restriction enzyme digestion 
analysis. Selected recombinant vectors were called pAdEasy-Gp120 and were then 
transformed into E. coli DH5" bacteria to amplify in large amount for HEK-293 cells 
transfection (to generate AdV) 
 Digestion of pAdEasy-Gp120 with Pac-I liberated a 3.5 or 4 kb fragment. 
Completely digested pAdEasy-Gp120 was purified in phenol:chloroform:isoamyl alcohol 
(25:24:1) followed by ethanol precipitation. The resultant digested product was dissolved 
in sterile water for transfection. 
4.7.2 Transfection of HEK-293 cells for AdV production 
AdV propagation and amplification was performed as described previously (169), 
(170). After purification and confirmation of recombinant adenoviral vector (pAdEasy-
Gp120), HEK-293-39 cells were transfected with the Pac-I digested pAdEasy-Gp120 to 
generate AdV using lipofectamine-2000 (Invitrogen-11668-019) reagent. pmax-GFP-
transfected 293-39 cells were used to assess the transfection efficiency. After 
transfectoin, flasks were maintained for 10 to 12 days for virus plaque formation. Cells 
were harvested in EMEM serum-free medium when extensive cytopathic effect observed. 
Then cells were subjected to five rounds of freeze and thaw cycles by placing them at -
80oC and 37oC temperatures, respectively, to obtain crude-viral-lysate (CVL). This was 
used to infect fresh HEK-293-26 cells to amplify AdV for further infection. HEK-293-26 
lysates were used to confirm Gp120 mRNA and protein expression by RT-PCR and 
! %(!
western blotting, respectively. For final AdVGp120 amplification, CVL was used to infect 
HEK-293-26 cells (35 T-175 cm2 culture flasks at 85% cell confluence). 
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Figure 4.1 Schematic representation of AdEasy system and AdV production 
(adopted from Qbiogene, Inc). 
Gp120 gene was cloned into pShuttleCMV, AdV entry vector, and it was linearized by 
Pme-I digestion. pShuttleCMV-Gp120 vector was transformed into electrocompetent E 
coli BJ5183 cells with pAdEasy-RGD for homologous recombination. Resulting 
recombinant pAdEasy-Gp120 adenovector was linearized by PacI digestion and 
transfected into HEK-293 cells for replication-deficient AdVGp120 production. 
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4.7.3 Purification of AdV 
When more than a 50% cytopathic-effect was observed in the last step of 
amplification, entire cells were harvested in PBS or serum-free EMEM and subjected to 
four rounds of freeze and thaw cycles as mentioned above. Subsequently, the samples 
were centrifuged at 10,000 rpm for 30 min in a JA-20 rotor (Beckman Coulter) at 4oC to 
remove as much cell debris and proteins as possible, which otherwise may interfere with 
virus purification. After centrifugation, supernatants were collected for discontinuous 
CsCl density-gradient ultracentrifugation.  
CsCl density-gradient ultracentrifugation was performed using quick seal 
centrifuge tubes layered with 1.25g/ml CsCl and 1.40g/ml CsCl gradient solutions. CVL 
was layered slowly above the density gradient solutions and subjected to 
ultracentrifugation for 2 hr at 45,000 rpm (145,000 X g) in a 80Ti rotor (Beckman 
Coulter) at 20o C.  The opalescent viral band was collected and layered on a 1.34 g/ml 
CsCl gradient solution and centrifuged again at 145,000 X g for about 18 hr at 20oC to 
separate infectious AdV particles from defective particles. After centrifugation, the lower 
viral band was collected. Salts present in the purified AdV samples were removed by 
dialysis using Slide-A-lyzer dialysis cassettes (Pierce) by following the manufacturer’s 
instructions. Finally, the concentration of the AdV was determined in spectrophotometry 
at A260 as described in Xiang and Wu et al. (171). Optical density of 1 is equivalent to 1 
X 1010 plaque forming unit/ml. The virus was stored in sterile 10% (v/v) glycerol at -80oC 
until use.  
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4.7.4 AdVGp120 characterization 
After AdVGp120 purification, Gp120-gene insertion and protein expression was 
confirmed by PCR and western blot, respectively.  
4.7.4.1 PCR 
  To verify the presence of the Gp120 gene in purified AdVGp120, samples were 
treated with proteinase-K (20 mg/ml) for 1 hr at 56oC followed by enzyme inactivation at 
95oC for 5 min. For gene amplification, gene-specific primers Gp120-Forward, 5’ 
ATCTATGGTACCTCTAGAGCCCCTCCATG 3’ and GP120-Reverse, 5’- 
AGCTGTAAGCTTGGATCCTTAGCGCTTCTC 3’ were used. PCR was performed 
along with positive controls, cDNA of Gp120-transfected 293 cells or recombinant 
pAdEasy-Gp120 vector, as described in section 4.5.10.  
4.7.4.2 Western blot 
 Purified AdVGp120 samples were subjected to western blot along with the positive 
control, transfected HEK-293 cell lysate, to test for Gp120 protein expression. First, 
samples were run on 7.5% (v/v) SDS-polyacrylamide gel electrophoresis, and protein 
bands were transferred onto nitrocellulose membranes (Millipore). Membranes were 
blocked (LI-COR Odyssey blocking buffer- LI-COR Biosciences) and stained with 
primary Ab-specific for Gp120 (Cederlane; biotinylated goat anti-Gp120). After 
thoroughly washing with Tween-PBS, membranes were incubated with avidin-
IRDyeR700 and scanned in a LI-COR Odyssey scanner.  
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4.8 Transfection 
4.8.1 Liposome-mediated transfection  
 Lipofectamine-2000 (Invitrogen) is a liposome-based transfection reagent used to 
transfect HEK-293 cells with pAdEasy-Gp120 (recombinant AdV vector) to produce 
AdV. The day before transfection, 2 X 106 HEK-293-39 cells were seeded in T25cm2 
flasks. Transfection was performed following the manufacturer’s guidelines. Briefly, 5 µg 
of pac-I digested pAdEasy-Gp120 was mixed with lipofectamine (20 µl) reagent in serum 
free EMEM. The mixture was incubated at room temperature for 30 min, which leads to 
the formation of DNA-liposome complexes, then added to the flasks. The flasks were 
incubated for 4 hr then medium was replaced with fresh EMEM with 10% FBS. 
4.8.2 Nucleofector–V electroporation 
 Nucleofector-V transfection (Amaxon, VCA-1003) kit was used to transfect BL6-
10 and DC2.4 cells to achieve stable expression of Gp120 protein. BL6-10 and DC2.4 
cells in log phase growth were used for the transfection to increase transfection 
efficiency. Transfection was carried out following the manufacturer’s instructions using 2 
'g of pcDNA3.1HygroGp120 per reaction. The positive transfection control, pmax-GFP, 
was used to monitor transfection efficiency in a fluorescent microscopy or flow 
cytometry. Briefly, cells were centrifuged and supernatant was decanted completely. The 
cells were resuspended in Nucleofector-V solution at 2 X 106 cells per 100 'l and 2 'g of 
pcDNA3.1hygroGp120 or pmax-GFP was added. The required electric field was applied 
using the L-103 program on the machine as per the manufacturer’s specifications. 
Immediately after electroporation, 1 ml of warm medium was added, and cells were 
transferred to a 6-well plate containing 1 ml of pre-warmed medium.  
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After 24-36 hr were allowed for expression of the transfected gene. Then 
hygromycin drug was added to transfected cells at the concentration of 3 to 3.5 mg/ml to 
select stable transfectants. On day 3, the medium was replaced with fresh medium 
containing 0.5 mg/ml hygromycin and the plates were maintained for 7-8 days. New 
clones growing in the presence of the drug were selected and maintained further under 
0.5 mg/ml hygromycin drug pressure. After assessing mRNA expression by RT-PCR, 
high Gp120-expressing clones were selected. To obtain stable transfectants, the clones 
were serially diluted and plated in 96 well (1 to 2 cell(s)/well), and maintained for 10-12 
days.  Then, two to three new clones were selected to confirm Gp120 mRNA and protein 
expression.  
 
4.9 Western blotting 
4.9.1 Transfected cells 
To determine the expression of Gp120 protein in the BL6-10 and DC2.4 
transfected cell lines, cell lysates were prepared using a mammalian cell lysis kit (Sigma). 
Protein concentration of samples was determined by the Bradford method (Bio-Rad).  
Protein samples for western blot were prepared by adding equal amounts of 2X sample 
buffer to cell lysates and boiling at 95oC for 5 min. About 30 µg of prepared protein 
samples were subjected to SDS-polyacrylamide gel electrophoresis and protein bands 
were transferred onto nitrocellulose membranes (Millipore). Membranes were blocked 
overnight in blocking buffer (LI-COR Odyssey). To detect the protein of interest, 
membranes were stained with biotin-conjugated anti-Gp120 Abs, then with avidin-
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IRDyeR700CW-conjugated Abs. The florescence intensity of the membranes was read 
with a LI-COR Odyssey scanner at 680 nm according to the manufacturer’s instructions.   
4.9.2 EXOs 
EXOs were also subjected to western blot to analyze DC- and EXO-specific 
marker expression. Approximately, 20 µg of EXOs were dissolved in 2X sample buffer. 
Similarly, as described above (section 4.9.1), proteins were separated by SDS-
polyacrylamide gel electrophoresis, and transferred onto nitrocellulose membranes 
(Millipore) for western blotting. Membranes were stained with marker-specific Abs to 
detect the protein of interest. To detect CD54, LAMP-1, CD86 and calnexins molecules, 
marker-specific Abs were used to stain the membranes, followed by staining with anti-
rat-IRDyeRCW800 or anti-mouse-IRDyeRCW700 secondary Abs. Finally, membranes 
were scanned at 680 or 800 nm in a LI-COR Odyssey instrument following the 
manufacturer’s instructions.  
 
4.10 Immunological techniques  
4.10.1 Purification of lymphocytes  
4.10.1.1 Nylon wool column separation 
 Prior to spleen harvest, nylon wool columns were saturated with complete medium 
and incubated for 40-50 min at 37oC. Spleens were harvested aseptically from naïve 
mice, and single cell suspensions were prepared. Red blood cells (RBCs) were depleted 
using 0.85% (w/v) Tris-ammonium chloride lysis buffer; splenocytes were washed twice 
in PBS and incubated in pre-warmed nylon columns for 1 hr. After incubation, columns 
were washed with 10-15 ml of RPMI medium (with 10% (v/v) FBS) to obtain an 
! &%!
enriched T cell population.  
4.10.1.2 Magnetic bead separation (positive selection)  
 Specific T lymphocyte subtypes were purified using para-magnetic microbeads 
following the manufacturer’s instructions. Briefly, for CD8+ T cell purification, enriched 
T cells or concanavalin A (ConA)-activated splenocytes were incubated with anti-
CD8!(Ly-2) para-magnetic microbeads for 20 min at 4oC in 0.5% (v/v) bovine serum 
albumin buffer, and washed in buffer by centrifuging at 1200 rpm for 10 min in a JA-10 
rotor (Beckman Coulter). Positive selection was performed using LS column (Miltenyi 
Biotec) following the manufacturer’s guidelines to separate the magnetically bound cells 
from unbound cells.  
4.10.2 Preparation of BMDCs 
BMDCs were generated from C57BL/6, different gene KO or A2-Kb mice as 
described previously (164). First, bone marrow from the femors and tibia were collected 
and homogeneous single cell suspensions were prepared. RBCs were depleted using 
0.85% (v/v) tris-NH4Cl2 lysis buffer. Bone marrow cells were washed and cultured in 
DMEM medium supplemented with 10% (v/v) FBS, GM-CSF (20 ng/ml) and IL-4 (20 
ng/ml). On day 2, floating cells, consisting of granulocytes, and T and B lymphocytes, 
were removed and the remaining cells were cultured with fresh medium. On day 4, 
proliferating aggregates of DCs were observed; the old medium was replaced with fresh 
medium. On day 6, cells slightly adherent to the plate were observed and these cells were 
pulsed with 0.4 mg/ml OVA in the presence of lipopolysaccharide for 8 to 16 hr. The 
resultant DCs are referred to as DCOVA. DCOVA generated from Kb-/- and CD40L-/- gene-
KO mice were called (Kb-/-)DCOVA and (CD40L-/-)DCOVA, respectively. BMDCs 
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generated from the A2-Kb mice were transduced with AdVGp120 at multiplicity of 
infection (MOI) 150 to get DCGp120. DC culture supernatants were collected for EXO 
preparation by ultracentrifugation.  
4.10.3 ConA activated CD8+ T (CD8+ aT) cell preparation 
 Naïve C57BL/6 or A2-Kb mice spleens were collected aseptically and single cell 
suspensions were prepared. RBCs were depleted using 0.85% (v/v) tris NH4Cl2 lysis 
buffer, and the splenocytes were cultured in RPMI-1640 medium containing 10% FBS 
(v/v), IL-2 (20 U/ml) and ConA (1 mg/ml) for 3 days. Finally, CD8+ aT cells were 
enriched using Histopaque-1077 (Sigma).  
4.10.4 OVA-aTexo or Gp120-aTexo vaccine preparation  
 Previously, a protocol was established for optimal exosomal molecule acquisition 
by activated T cells (150). Briefly, ConA CD8+ aT cells were co-cultured with EXOOVA 
or Gp120-specific EXOs (EXOGp120) (10 'g EXOs/1 X 106 T cells) in serum-free 
medium containing IL-2 (20 U/ml) for 4-5 hr at 37oC. These cells were termed as OVA-
aTexo or Gp120-aTexo cells. CD8+aT cells incubated with EXOOVA(Kb-/-) were termed 
as (Kb-/-)aTexo. Similarly, CD8+aT(CD40L-/-) incubated with EXOOVA(CD40L-/-) were 
termed as (CD40L-/-)aTexo. These different OVA-aTexo are similar to the normal OVA-
aTexo, but deficient in designated molecular expression. Both OVA-aTexo and Gp120-
aTexo cells were analyzed by flow cytometry to detect the presence of exosomal 
molecules on the cell surface after staining with Abs specific for EXO markers.  
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4.10.5 DC2.4Gp120 maturation 
 DC2.4Gp120 cell maturation was achieved by culturing overnight in AIM-V serum 
free medium containing IFN-! (20 ng/ml) and GM-CSF (1 ng/ml). After 8-16 hr, the 
mature DC2.4Gp120 cells were analyzed by flow cytometry with a panel of Abs specific for 
DC maturation and activation markers. The culture supernatant was collected and stored 
at -80oC for EXO purification. 
4.10.6 Transduction of BMDCs with AdVGp120 
AdVGp120 produced in this study contains a RGD-modified fiber domain, which 
enhances virus infection and transgene expression in BMDCs. DCs were transduced with 
AdVGp120 as described previously (125).! Briefly, A2-Kb BMDCs were infected with 
AdVGp120 for 1 hr at 37oC in DC culture medium at a MOI of 150, then the medium was 
replaced. DCs were cultured for another 24 hr to achieve optimal transgene expression. 
These DCs are called as DCGp120. DC culture supernatants were collected and stored at -
80oC for EXO purification. 
 
4.10.7 Flow cytometry staining 
4.10.7.1 Cell staining 
Cells (DCs, T cells or tumor cells) (1 X 106) were pelleted at 3100 rpm for 3 min 
using a SEROFUGE-II centrifuge and re-suspended in 100 'l of PBS. About 1 to 5 µg/ml 
of FITC, PE or biotin-conjugated Abs were added and cells were incubated on ice for 30 
min in the dark and then washed twice with cold PBS. Cells were re-suspended in 100 'l 
PBS if secondary Ab staining was necessary. Finally, cells were washed in cold PBS and 
re-suspended in 400 'l of PBS for flow cytometry analysis (Beckman Coulter) and were 
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analyzed fresh. Cells were stained with irrelevant isotype-matched Abs were used as 
controls. Expression profiles are presented in histograms of fluorescence intensity (log10) 
of FITC on X-axis and the number of DC, CD8+ aT, OVA/Gp120-aTexo or tumor cells 
on the Y-axis. A total of 30,000 events were analyzed by flow cytometry for each marker.  
4.10.7.2 EXO staining 
 Abs conjugated with FITC were used for the EXOs staining. About 1 µl of 50 
µg/ml of FITC-conjugated Abs were added to the 20-40 'g EXOs re-suspended in 100 'l 
PBS and incubated for 30 min on ice. The samples were further diluted with PBS (final 
volume 300-400 'l) and analyzed by flow cytometry. Expression profiles are presented in 
histograms of fluorescence intensity (log10) of FITC on X-axis (analyzed for Kb/HLA-A2, 
Iab, CD11c, CD54, CD80, CD86 and pMHC-1 expression) and the number of EXOs on 
the Y-axis. A total of 30,000 events were analyzed by flow cytometry for each marker.  
4.10.8 In vivo cytotoxicity assay 
In vivo cytotoxicity was assessed as described previously (164). Briefly, 
splenocytes collected from naïve mice were labeled differentially with high (3.0 'M) and 
low (0.6 'M) concentration of CFSE dye. High CFSE-labeled cells, pulsed with OVA-I 
peptide, (SIINFEKL) or Gp120 peptide, (KLTPLCVTL), act as target cells; and low 
CFSE-labeled cells, pulsed with non-specific peptide, act as control cells. Both target and 
control cells (1 X 106 of each) were then adoptively transferred at a 1:1 ratio into 
immunized and control mice on day 7 of immunization. After 16 hr of adoptive transfer, 
spleens were removed from the mice and analyzed to determine the proportion of target 
cell lysis (CFSEhigh) in comparison to control cells (CFSElow) by flow cytometry. Profiles 
presented are histograms of fluorescence intensity (log10) of CFSElow and CFSEhigh on X-
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axis and number of splenocytes on the Y-axis. An average of 1000 labelled targets 
remaining in the spleen were analyzed by flow cytometry for each sample. The number of 
residual CFSEhigh and CFSElow cells in spleen is presented in each figure.  
4.10.9 In vivo tetramer proliferation assay 
 On day 6 of vaccination or immunization, 60 'l of peripheral blood was collected 
in 40 'l of heparin. Blood samples were incubated with PE-conjugated H2-Kb/OVA257-264 
(Beckman Coulter) or HLA-2/Gp120121-129 (National Institute of Health) tetramer and 
FITC-CD8 Ab for 30-40 min at room temperature. The samples were fixed and treated 
with lysis buffer (Beckman Coulter) to remove RBCs, washed twice and finally 
resuspended in 400 'l PBS. In flow cytometric analysis of each sample, lymphocyte 
population was gated based on their size (FSC; forward scatter) and granularity (SSC; 
side scatter) and used in the analysis. A total of 0.2 X 106 cells (events) were used for 
analysis in each sample. Flow cytometry profiles are presented as dot-scatter plots. In 
each dot-scatter plot, X-axis represents fluorescence intensity of FITC (CD8 molecule 
expression) and Y-axis represents fluorescence intensity of PE (OVA-specific TCR).  
The value in each plot represents percentage of tetramer+CD8+ T cells in total CD8+ 
population.  
4.10.10 Intracellular IFN-#  cytokine secretion assay 
4.10.10.1 Peptide stimulation 
This assay was performed as described (172) using a Cell 
Fixative/Permeabilization intracellular cytokine analysis kit (BD Bioscience). Briefly, the 
blood samples were collected and RBCs were depleted using Tris-NH4Cl2 lysis buffer. 
Peripheral blood mononuclear cells were harvested in 500 'l RPMI-1640 with 10% (v/v) 
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FBS and stimulated with 2 'M of Gp120 peptide (KLTPLCVTL) for 5 hr in the presence 
of 2 'M GolgiStop (BD Biosciences) in U-bottom culture plates. Stimulated cells were 
washed with PBS, stained with anti-CD8-FITC Abs and fixed using cytofix/cytoperm 
solution (BD Biosciences). The samples were washed twice in 1X wash buffer (BD 
Bioscience) and stained with anti-IFN-!-PE Abs for 30 min. Finally, samples were 
washed twice and resuspended in 400 'l of 1X wash buffer. The samples were analyzed 
in lymphocyte-gated population by flow cytometry to see the percent Gp120-specific 
CTLs that secrete IFN-! cytokine. A total of 0.2 X 106 cells (events) were used for 
analysis in each sample. Flow cytometry profiles are presented as dot-scatter plots. In 
each dot-scatter plot, X-axis represents fluorescence intensity of FITC (CD8 molecule 
expression) and Y-axis represents fluorescence intensity of PE (IFN-!+ lymphocytes).  
The value in each plot represents percentage of IFN-!+CD8+ T cells in total CD8+ 
population.  
4.10.10.2 Cell activator or mitogen stimulation  
Whole blood samples (around 200 'l) were collected from immunized or control 
mice in heparin and diluted with equal volume of RPMI-1640 medium. Samples were 
incubated with cell activators, phorbol myristate acetate (50 ng/ml), calcium ionophore (1 
µg/ml), and transport inhibitor GolgiStop (BD Biosciences) for 4 hr at 37oC. Then 
samples were washed twice with serum-free medium or PBS. Intracellular IFN-! staining 
and flow cytometry analysis was performed as described in section 4.10.10.1. 
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4.11 EXO purification 
EXOs were purified from DCOVA, DC2.4Gp120 or DCGp120 culture supernatants as 
described previously (150). Briefly, EXOs were isolated by differential centrifugations; 
initial centrifugation at 300 X g to remove cells, cellular debris and protein aggregates, 
and final centrifugation (in quick seal centrifuge tubes) at 100,000 X g in a 80Ti rotor 
(Beckman Coulter) for 1 hr to pellet out the EXOs. EXOs were washed twice with PBS 
and quantified with the Bradford method (Bio-Rad). EXOs derived from DCOVA, (Kb-
/)DCOVA, and (CD40L-/-)DCOVA were termed as EXOOVA, EXOOVA(Kb-/-) and 
EXOOVA(CD40L-/-), respectively. EXOs purified from DC2.4Gp120 and DCGp120 were 
called EXOGp120. An average of 10 'g EXOOVA or EXOGp120 was recovered from an 
overnight-cultured 1 X 106 DCs.    
 
4.12 Electron microscopic analysis of EXOs 
 Purified EXOs were fixed in 4% (w/v) Para-formaldehyde. They were loaded on 
carbon-coated formvar grids and incubated for 20 min in a moist chamber. Later, the 
samples were washed twice with PBS and fixed in 1% (w/v) glutaraldehyde for 5 min. 
The samples were then washed three times with PBS and stained with aqueous uranyl for 
10 min. The EXOs were finally examined with a JEOL 1200EX electron microscope at 
60KV. 
 
4.13 Histopathological analyses 
 Lung tissues were collected on day 24 of tumor challenge from immunized or un-
immunized groups. These lung samples were fixed in 10% (w/v) formaldehyde, 
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embedded in paraffin, sliced into 6-7 µm sections and stained with hematoxylin-eosin 
dye according to standard protocols. 
 
4.14 Mouse immunization 
 Four- to six-week-old C57BL/6 and A2-Kb mice were used for the experiment. 
Mice were immunized intravenously (IV) with 2 X 106 DCOVA, DC2.4Gp120 or DCGp120 
and 4 X 106 OVA-aTexo or Gp120-aTexo cells per mouse. PBS- and CD8+ aT (4 X 
106/mouse)-injected mice were used as controls. On day 6, the peripheral blood samples 
were analyzed in tetramer assay for proliferating Ag-specific CD8+ T cells. 
 
4.15 Tumor protection study  
C57BL/6 mice and A2-Kb transgenic mice were immunized with DCGp120 and 
Gp120-aTexo cells. On day 6 and day 30 post immunization, mice were challenged with 
the BL6-10Gp120 or BL6-10Gp120/A2-Kb tumor cells (0.5 X 106 cells/mouse). Mice injected 
with PBS or CD8+ aT cells were used as controls. All mice were sacrificed on day 24 of 
tumor challenge, and visible tumor colonies in lungs were counted. Tumors appear as 
black-pigmented colonies and are easily distinguished from the surrounding healthy 
tissue. If the tumor colonies are too many and difficult to count, an arbitrary value of 
>100 was assigned. 
 
4.16 Statistical analysis 
 Statistical analysis was performed using Graphpad Prism Software. The results 
are presented as mean ± standard deviation (SD) unless specified.! The statistical 
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significance between two or more groups was analyzed by Student’s t-test or one-way 
analysis of variance (Tukey’s post hoc test), respectively. P value less than 0.05 was 
considered significant. 
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CHAPTER 5 
RESULTS 
PART A 
5.1 OVA-specific CD8+aTexo vaccine stimulates primary and memory 
CD8+ CTL responses 
5.1.1 DCOVA and EXOOVA express immuno-stimulatory molecules  
DCs play a crucial role in activation of T cells to induce Ag-specific immune 
responses. DCs convert protein Ags to peptides and display them on MHC molecules for 
T cell recognition and provide additional stimuli (co-stimulators) to T cells for complete 
activation. Therefore, cultured DCOVA cells were characterized phenotypically with flow 
cytometry by staining with a panel of Abs specific for DC maturation, co-stimulatory 
molecules, and Ag presentation. DCOVA showed higher expression of co-stimulatory 
molecules, CD54, CD80 and CD86; MHC molecules, Kb and Iab; and the DC-specific 
marker, CD11c, suggesting Ag-presenting ability of mature DCOVA (Figure 5.1).  
Many studies have shown that membrane-associated proteins are major 
components of DC-derived EXOs (138, 146). In this study, EXOs were analyzed in flow 
cytometry to examine the expression of membrane proteins. EXOs purified from DCOVA 
culture supernatant by ultracentrifugation were termed as EXOOVA. For phenotypic 
characterization, EXOOVA were stained with a panel of Abs specific for co-stimulatory 
molecules, MHC class I and II molecules and a DC-specific marker and analyzed by flow 
cytometry. As expected, expression of CD80 and CD86 co-stimulatory molecules, CD54, 
CD11c, and MHC class I and II activation markers was observed in EXO, but the levels 
were appeared to be ~10 times less compared to expression levels of DCOVA. Since the 
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size EXO ($100nm) is much lesser than a DC (15-20µm) and immunostimulatory 
molecules expression levels of the EXO is lesser when compared to DC, a high 
concentration (10 µg per 1 X 106 ConA CD8+ T cells) of EXOs was used to prepare 
OVA-aTexo cells, and a high dose of 4 X 106 OVA-aTexo cells, which is twice the 
number of DCs, were used for the immunization. In flow cytometry analysis, DC 
population was gated based on FSC and SSC dot plots and used to obtain histogram 
fluorescence (FITC) on FL1 channel. A total of 8000 events of DC or EXOs, 
respectively, were analyzed for each marker. DCOVA and EXOOVA were analyzed in flow 
cytometry every time they were prepared (at least 3-4 times) to verify the quality of 
purification.  
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Figure 5.1 Phenotypic characterization of mature DCOVA and EXOOVA. Mature 
DCOVA and EXOOVA were stained with a panel of FITC-conjugated Abs specific for DC 
maturation markers, MHC class I and II molecules, and other DC-specific markers (solid 
thick line) or with irrelevant isotype-matched Ab controls (dotted thin line), and analyzed 
by flow cytometry. In each figure, X-axis represents histograms of fluorescence intensity 
(log10) of FITC (analyzed for Kb, Iab, CD11c, CD54, CD80, CD86 and pMHC-1 
expression) and Y-axis represents the relative number of DCs or EXOs. Data presented 
are from a single analysis of an independent experiment.  
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5.1.2 Acquisition of exosomal molecules by ConA CD8+ aT cells 
ConA CD8+ aT cells were purified to >90% purity by positive selection using 
anti-mouse CD8+ paramagnetic beads (Figure 5.2A). Purified CD8+ aT cells were co-
cultured with EXOOVA in the presence of IL-2 for 5 hr, which allowed up take of 
exosomal molecules. After exosomal molecule acquisition, CD8+ aT cells are called 
OVA-aTexo cells. Both CD8+ aT and OVA-aTexo cells were stained with a panel Abs 
specific for activation markers (CD25), co-stimulatory molecules (CD80) and pMHC-I 
molecules, and analyzed by flow cytometry (Figure 5.2B). In comparison with ConA 
CD8+ aT cells, increased CD80, and pMHC-I molecules on OVA-aTexo cells clearly 
suggest the transfer of exosomal proteins, immunostimulatory molecules, on to active 
CD8+ T cells. In flow cytometric analysis, lymphocyte population was gated based on 
forward versus side scatter dot plot and used to obtain histogram of fluorescence of FITC 
on FL1. A total of 30,000 events of CD8+ aT or OVA-aTexo were used for analysis for 
each marker. OVA-aTexo cells were analyzed in flow cytometry at least 3 times in 
independent experiemnts, and data presented below are from a single analysis of an 
independent experiment.  
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Figure 5.2 Acquisition of exosomal markers specific for mature DCOVA on OVA-
aTexo cells. A) Purity of the CD8+ aT cells after magnetic bead separation. B) The CD8+ 
aT and OVA-aTexo cells were incubated with a panel of Abs specific for T cell activation 
and DC-specific markers (solid thick lines) and analyzed by flow cytometry. Irrelevant 
isotype-matched Abs (dotted thin lines) were used as controls. In each figure, X-axis 
represents histograms of fluorescence intensity (log10) of FITC (analyzed for CD8, Kb, 
Iab, CD25, CD80 and pMHC-1 expression) and Y-axis represents the relative number of 
CD8+ aT or OVA-aTexo cells. A total of 30,000 events of CD8+ aT or OVA-aTexo were 
used for analysis for each marker. OVA-aTexo cells were analyzed in flow cytometry at 
least 3 times in independent experiments, and data presented below are from a single 
analysis of an independent experiment.  
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5.1.3 OVA-aTexo vaccine stimulates proliferation of OVA-specific CD8+ T cells in 
vivo 
Following immunization of C57BL/6 mice with 4 X 106 OVA-aTexo cells, or 2 X 
106 DCOVA, the proliferated OVA-specific CD8+ T cells in peripheral blood was 
monitored by H2-Kb/OVA257-264 tetramer staining on day 3, 4, 5, 6, 7, 9 and 30 after 
immunization,. In whole blood samples, the lymphocyte population was gated based on 
forward and side scatter properties and used for the analysis by flow cytometry. A total of 
0.2 X 106 cells (events) were used for analysis in each sample. Flow cytometry profiles 
are presented as dot-scatter plots. Experiment was performed twice, each of which 
contained 4 mice per test group. For statistical analysis, the values from both first and 
second experiments were used. Mean% ± 1 S.D (n=8) of OVA-specific CD8+ T cells out 
of the total CD8+ T cell population in DCOVA- and OVA-aTexo-immunized groups was 
indicated: ** p<0.01 when compared with PBS or CD8+ aT-injected groups.  
. The results indicate the kinetics and magnitude of CD8+ T-cell generation by 
OVA-aTexo cells are similar to those of DCOVA, where peak tetramer-positive CD8+ T 
cells were observed on day 6 and 7 post-immunization (Figure 5.3A).   
OVA-aTexo cells and DCOVA induced an average of 1.12% ±1 0.1 and 1.42% ±1 
0.15 OVA-specific CD8+ T cells out of total CD8+ T cells on day 6 after immunization 
(Figure 5.3B). However, there was no response in control mice that were injected with 
PBS or CD8+ aT cells (negative controls), suggesting that OVA-aTexo cells can induce a 
CD8+ T-cell response similar to DCOVA in an Ag-specific manner.  
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Figure 5.3 OVA-aTexo vaccine induces primary CD8+ T-cell response in vivo. Wild-
type mice were injected IV with DCOVA, OVA-aTexo, CD8+ aT or PBS. A) Tail blood 
samples were collected from injected mice on day 3, 4, 5, 6, 7, 9 and 30, stained with PE-
H2-Kb/OVA1 tetramer and FITC-anti-CD8 Ab, and analyzed by flow cytometry. Values 
in line diagram represent the Mean% ± 1 S.D of OVA-specific CD8+ T cells in total 
CD8+ T cells and are cumulative of two independent experiments with 4 mice per group 
B) The scatter-dot plots are derived from a representative mouse in each group on day 6 
post-immunization. In flow cytometric analysis, a total of 0.2 X 106 cells in lymphocyte-
gated population were used for analysis in each sample. In each dot-scatter plot, X-axis 
represents fluorescence intensity of FITC (CD8 molecule expression) and Y-axis 
represents fluorescence intensity of PE (OVA-specific TCR). The net percentage of 
! (+!
labelled cells within the gated analysis region is presented in each figure. Data presented 
is from a single analysis of an independent experiment. 
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5.1.4 OVA-aTexo vaccine stimulates cytotoxic CD8+ T cells 
Whether OVA-specific CD8+ T cells exhibit cytotoxic function was assessed by 
an in vivo cytotoxicity assay. Wild-type mice were injected with OVA-aTexo, DCOVA, 
CD8+ aT or PBS, and monitored for CD8+ T cells proliferation by tetramer assay as 
described above on day 6 after immunization. The data is presented as mean% ± 1 S.D 
(n=8) of OVA-specific CD8+ T cells out of the total CD8+ T cell population in DCOVA 
and OVA-aTexo groups: * p<0.05 when compared with PBS or CD8+ aT-injected 
groups. In in vivo cytotoxicity assay, on day 7, the above-immunized mice were 
adoptively transferred with equal number of target (CFSEhigh-labeled, OVA1-pulsed 
splenocytes) and control (CFSElow-labeled, irrelevant Mut1-peptide-pulsed splenocytes) 
cells. After 16 hr of adoptive transfer, spleens were removed and analyzed by flow 
cytometry to determine the proportion of target cell lysis (CFSEhigh) in comparison to 
control cells (CFSElow). An average of 1000 CFSE-labelled cells remaining in the spleen 
were analyzed by flow cytometry for each sample, and data is presented as mean% ± 1 
S.D (n=8) of target (CFSEhigh) and control (CFSElow) cells remaining in the spleens of 
mice injected with DCOVA, OVA-aTexo, CD8+ aT or PBS groups was indicated: ** 
p<0.01 when compared with PBS or CD8+ aT-injected groups. For statistical analysis, the 
values of both first and second experiments with four mice per group were used. 
OVA-aTexo, DCOVA, CD8+ aT or PBS groups respectively showed an average of 
1.15% ±1 0.2, 1.65% ±1 0.3, 0.05% ±1 0.02 and 0.02% ±1 0.01 CD8+ T cells by tetramer 
analysis (Figure 5.4A). Similarly, the vaccine-stimulated CTLs were able to lyse the 
target cells efficiently. Mice immunized with OVA-aTexo, DCOVA or CD8+ aT cells 
showed an average lysis of 70% ±1 1.2, 71% ±1 1.1 or 4% ±1 3.1 CFSEhigh-labeled target 
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cells, respectively (Figure 5.4B), suggesting OVA-aTexo vaccination-induced CTLs 
exhibit cytotoxic activity similar to those of DCOVA-induced ones. 
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Figure 5.4 OVA-aTexo vaccine activates functional cytotoxic CD8+ T cells. Wild-type 
mice (n=4/group) were IV immunized with PBS, DCOVA, OVA-aTexo or CD8+ aT. A) 
On day 6, tail blood samples were collected and stained with PE-H2-Kb/OVA1 tetramer 
and FITC-anti-CD8 Ab to analyze tetramer-positive CD8+ CTLs by flow cytometry. The 
scatter-dot plots are derived from a representative mouse in each group on day 6 post 
immunization. In flow cytometric analysis, a total of 0.2 X 106 cells in lymphocyte-gated 
population were used for analysis in each sample. In each dot-scatter plot, X-axis 
represents fluorescence intensity of FITC (CD8 molecule expression) and Y-axis 
represents fluorescence intensity of PE (OVA-specific TCR). The net percentage of 
labeled cells within the gated analysis region is presented in each figure. Data presented 
is from a single analysis of an independent experiment. B) On day 7, the above 
immunized and control mice were injected IV with target and control labeled cells at 1:1 
ratio. After 16 hr of target cell delivery, the percentage of residual CFSEhigh target cells 
remaining in the spleen in comparison to control CFSElow cells was determined using 
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flow cytometry. In each figure, X-axis represents histograms of fluorescence intensity 
(log10) of CFSElow and CFSEhigh and Y-axis represents the relative number of labeled 
cells. An average of 1,000 labeled cells were analyzed by flow cytometry for each 
sample. The values in each figure represent the residual CFSEhigh and CFSElow cells 
remaining in the spleen. Data presented is from a single analysis of an independent 
experiment.  
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5.1.5 OVA-aTexo vaccine induces Ag-specific memory response 
To determine whether CD8+ memory T cells are induced by the OVA-aTexo 
vaccine, mice were immunized with OVA-aTexo, DCOVA or PBS. All groups were 
boosted with DCOVA on day 30 post-immunization. The blood samples were analyzed on 
day 4 of DCOVA boost in the tetramer assay to assess expansion of memory cells. In 
whole blood samples, the lymphocyte population was gated and used for the analysis by 
flow cytometry. A total of 0.2 X 106 cells (events) were used for analysis in each sample. 
Flow cytometry profiles are presented as dot-scatter plots. Mice used for the kinetics and 
primary immune response study (section 5.1.3) were used for the memory response study, 
and statistical analysis was performed similarly as described in this section. The mean 
percentage (n=8) and 1 S.D values of tetramer positive cells in total CD8+ T cells 
population on day 30 post-immunization and 4 days after DCOVA boost was calculated for 
each group. Mean% ± 1 S.D (n=8) of OVA-specific CD8+ T cells out of the total CD8+ T 
cell population in DCOVA and OVA-aTexo groups was indicated: ** p<0.01 when 
compared with PBS group.  
On the 30th day after primary immunization, the immunized groups had mean 
average of 0.09% ±1 0.03 and 0.07% ±1 0.02 response in DCOVA- and OVA-aTexo-
immunized mice, respectively (Figure 5.5). Interestingly, OVA-aTexo cells also induced 
memory cells that were able to expand (up to 1.2% ±1 0.15) as that induced by DCOVA (up 
to 1.55% ±1 0.2), suggesting OVA-aTexo cells have ability to induce a memory T cells 
response.   
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Figure 5.5 OVA-aTexo vaccine induces memory CD8+ T cells. Wild-type mice were 
injected IV with DCOVA, OVA-aTexo or PBS. After 30 days, blood samples were 
collected and stained in the tetramer assay to assess presence of OVA-specific CD8 T 
cells. All mice were boosted with DCOVA, and expansion of memory T cells was 
examined 4 days later by the tetramer assay. The scatter-dot plots presented are derived 
from a representative mouse in each group. In flow cytometric analysis, a total of 0.2 X 
106 cells in lymphocyte-gated population were used for analysis in each sample. In each 
dot-scatter plot, X-axis represents fluorescence intensity of FITC (CD8 molecule 
expression) and Y-axis represents fluorescence intensity of PE (OVA-specific TCR). The 
net percentage of labeled cells within the gated analysis region is presented in each 
figure. Data presented is from a single analysis of an independent experiment. 
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5.1.6 OVA-aTexo vaccine activation of CD8+ T cells is mediated through CD40L 
signaling, IL-2 secretion and acquired pMHC-I complex 
It has been shown previously that CD4+aTexo vaccine is able to stimulate a strong 
CD8+ CTL response and anti-tumor immunity through CD40L-signaling, CD80 co-
stimulation and acquired pMHC-I complexes. Both the OVA-aTexo and CD4+aTexo 
vaccine showed similar immuno-stimulatory capacity. This experiment investigated the 
OVA-aTexo vaccine mechanism of immuno-stimulation. OVA-aTexo cells with or 
without specific molecular deficiencies were injected into wild-type or gene-deficient 
mouse (IL-2R-/-) as shown in Table 5.1. Immune response was measured by both in vivo 
CD8+ T cell proliferation and cytotoxicity assays as described in section 5.4. In tetramer 
study, mean% ± 1 S.D (n=8) of OVA-specific CD8+ T cells out of the total CD8+ T cell 
population in wild-type groups immunized with OVA-aTexo, (CD40L-/-)aTexo or (Kb-/-
)aTexo cells and IL-2R-/- mice immunized with OVA-aTexo cells were indicated: 
*p<0.05 when compared to OVA-aTexo-injected wild-type mice. In in vivo cytotoxicity 
assay, the data is presented as mean% ± 1 S.D (n=8) of target (CFSEhigh) cells remaining 
in the spleens of wild-type groups immunized with OVA-aTexo, (CD40L-/-)aTexo or (Kb-
/-)aTexo cells, and IL-2R-/- mice immunized with OVA-aTexo cells was indicated: * 
p<0.05 when compared with PBS or CD8+ aT-injected groups. For statistical analysis, the 
values of both first and second experiments with four mice per group were used in the 
above experiments. 
Mice immunized with (CD40L-/-)aTexo showed significantly less proliferation of 
tetramer-positive CD8+ T cells (0.65% ±1 0.1) compared to the OVA-aTexo-injected 
mice (Figure 5.6A). Similarly, (Kb-/-)aTexo-immunized mice failed to show any 
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proliferation of OVA-specific CD8+ T cells (0.05% ±1 0.01) compare to mice immunized 
with OVA-aTexo cells (1.1% ±1 0.2). Furthermore, IL-2R!-/- mice immunized with 
OVA-aTexo showed very little CD8+ T cells (0.15% ±1 0.05) proliferation. In contrast, 
wild-type mice immunized with OVA-aTexo showed an increase in proliferation of CD8+ 
T cells. Similarly, an efficient CD8+ CTL response capable of lysing target cells was 
observed by in vivo cytotoxicity assays in OVA-aTexo-immunized mice (Figure 5.6B). 
These results suggest that the OVA-aTexo stimulatory effect is mediated through CD40L 
signaling, IL-2 secretion and acquired pMHC-I molecules. 
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Table 5.1 Preparation of specific molecule-deficient OVA-aTexo vaccines 
OVA-aTexo vaccine 
types 
Source of CD8+ T cells Source of DC-derived EXOs 
OVA-aTexo  C57BL/6 mice (spleen) C57BL/6 mice (bone marrow) 
(CD40L-/-)aTexo  CD40L-/- mice (spleen) CD40L-/- mice (bone marrow) 
(Kb-/-)aTexo  Kb-/- mice (spleen) Kb-/- mice (bone marrow) 
Note: OVA-aTexo cells were injected into IL-2R"-/- mice to test the involvement of IL-2 
signaling in the activation of OVA-specific CD8+ T cells.  
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Figure 5.6 The mechanism of immuno-stimulation by OVA-aTexo vaccine. OVA-
aTexo cells deficient in designated molecules were injected into wild-type mice, and 
OVA-aTexo cells were injected into IL2R-/- mice. A) On day 6, peripheral blood samples 
were analyzed using the tetramer assay to quantify OVA-specific CD8+ T cells by flow 
cytometry. The scatter-dot plots presented are derived from a representative mouse in 
each group on day 6 post immunization. In flow cytometric analysis, a total of 0.2 X 106 
cells in lymphocyte-gated population were used for analysis in each sample. In each dot-
scatter plot, X-axis represents fluorescence intensity of FITC (CD8 molecule expression) 
and Y-axis represents fluorescence intensity of PE (OVA-specific TCR). The net 
percentage of labeled cells within the gated analysis region is presented in each figure. 
Data presented is from a single analysis of an independent experiment. B) In the in vivo 
cytotoxicity assay, on day 7, the above-immunized and -control mice were injected IV 
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with target and control labeled cells at 1:1 ratio. After 16 hr of target cell delivery, the 
percentage of residual CFSEhigh target cells remaining in the spleen in comparison to 
control CFSElow cells was determined by flow cytometry. In each figure, X-axis 
represents histograms of fluorescence intensity (log10) of CFSElow and CFSEhigh and Y-
axis represents the relative number of labeled cells. An average of 1,000 labeled cells 
were analyzed by flow cytometry for each sample. The values in each figure represent the 
residual CFSEhigh and CFSElow cells remaining in the spleen. Data presented is from a 
single analysis of an independent experiment.  
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PART B 
5.2 Gp120-aTexo vaccine activates naïve and memory CD8+ CTL 
responses and anti-tumor immunity in wild-type mice  
5.2.1 Characterization of DC2.4 cells transfected with Gp120  
DC2.4 cells are a type of DC cell lines. In this study, we transfected these cell 
lines with Gp120 so that the EXOs secreted from them might express Gp120-specific 
epitopes on MHC-I and -II molecules. DC2.4 cells were transfected with pcDNAGp-120-
Hygro expression vector while using pmax-GFP as a positive transfection control (Figure 
5.7A). After selecting transfected clones under hygromycin drug pressure, the cells were 
analyzed for Gp120 mRNA and protein expression in PCR and western blot, respectively. 
The positive colonies with confirmed Gp120 mRNA (Figure 5.7B) and protein (Figure 
5.7C) expression were chosen for EXO purification.  
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Figure 5.7 Characterization of DC2.4 cells transfected with Gp120. A) DC2.4 cells 
transfected with pmax-GFP were used as positive control to monitor transfection 
efficiency. Fluorescent microscopic image of cells to show the number of transfected 
cells on 24 hr post-transfection. B) and C) Potential positive clones were selected based 
on their growth with hygromycin selection. Selected clones were analyzed for Gp120 
mRNA expression by RT-PCR (B) and protein expression by western blot (C). 
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5.2.2 Characterization of BL6-10 melanoma cells transfected with Gp120  
At present, well-established murine models are unavailable for HIV-1 vaccine 
efficacy studies. Therefore, I employed a tumor challenge approach to evaluate the 
immunotherapeutic effect of the Gp120-aTexo vaccine. To do this, BL6-10 cells were 
transfected with pcDNAGp-120-Hygro expression vector while using pmax-GFP as a 
positive transfection control (Figure 5.8A). Gene expression was confirmed by PCR and 
western blot. BL6-10 tumor cells are highly metastasizing skin melanoma tumor cells and 
upon injection IV cause black-pigmented tumor nodules in lungs. The PCR and western 
blot analysis confirmed that selected BL6-10 transfected-clones express Gp120 
transcripts (Figure 5.8B) and protein (Figure 5.8C), respectively.  
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Figure 5.8 Characterization of BL6-10 melanoma cells transfected with Gp120. A) 
BL6-10 tumor cells were transfected with pmax-GFP to monitor transfection efficiency 
using the Nucleofector V kit. Fluorescent microscopic image of cells to show the number 
of transfected cells on 24 hr post-transfection. B) and C) Potential positive clones of BL6-
10 were selected based on growth in the presence of hygromycin. Selected clones were 
analyzed for Gp120 mRNA by RT-PCR (B) and protein expression by western blot (C).  
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5.2.3 Mature DC2.4Gp120 and their EXOs express immuno-stimulatory molecules  
As a part of the current study, Gp120-transfected DC2.4 cells were used as a 
substitute for BMDCs. DC2.4 cells were successfully transfected with an expression 
vector containing the full-length Gp120 gene sequence. DC2.4Gp120 cells were made to 
mature by culturing overnight in the presence of IFN-!. An average of 10 'g of EXOs 
were recovered from cultures of 1 X 106 mature DC2.4Gp120 cells. By flow cytometry, a 
total of 8000 events of DC EXOs were analyzed for each marker. The purified EXOs and 
mature DC2.4Gp120 showed the expression of maturation, co-stimulatory and activation 
markers, such as CD11c, CD54, CD80, CD86, Kb and Iab, (solid thick lines) (Figure 
5.9A). Irrelevant isotype-matched Abs (dotted thin lines) were used as controls. The 
expression profiles indicated that mature DC2.4Gp120 express activation and maturation 
markers similar to that of mature BM DCOVA. The EXOGp120 showed similar expression 
of all the markers, but likely at 10-fold reduced levels. As expected, expression of CD80 
and CD86 co-stimulatory molecules, CD54, CD11c, and MHC class I and II activation 
markers was observed in EXO, but the levels were appeared to be 10 times less compared 
to expression levels of DCOVA. DCOVA and EXOOVA were analyzed in flow cytometry 
every time when they were prepared (at least 3-4 times) to verify the quality of 
purification. 
 EXOs were further characterized in western blot to see the expression of LAMP-
1, CD54, CD86 and calnexin. In line with previous results (164), EXOs showed the 
expression of CD54, CD86, and additionally LAMP-1, but not calnexin, which is an 
endoplasmic reticulum-specific marker (Figure 5.9B). These results are similar to 
positive control EXOOVA, suggesting that EXOGp120 are derived from endosomal 
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pathways (173). EXOGp120 were also processed for electron microscopic visualization, 
which showed a characteristic “saucer” or “cup” like morphology similar to EXOOVA 
(Figure 5.9C).  
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Figure 5.9 Phenotypic characterization of DC2.4Gp120 and EXOGp120. A) DC2.4Gp120 
and EXOGp120 were stained with a panel of Abs specific for activation, co-stimulatory and 
maturation markers (solid thick lines) or with irrelevant isotype-matched control Abs 
(dotted thin lines), and analyzed by flow cytometry. In each figure, X-axis represents 
histograms of fluorescence intensity (log10) of FITC (analyzed for Kb, Iab, CD11c, CD54, 
CD80, CD86 and pMHC-1 expression) and Y-axis represents the relative number of DCs 
or EXOs. A total of 30,000 events of DC2.4Gp120 or EXOGp120 were used for analysis for 
each marker. Data presented are from a single analysis of an independent experiment.  B) 
The expression of LAMP-1, CD54, CD86 and calnexin were analyzed in EXOGp120 by 
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western blot using EXOOVA as a positive control. C. Electron microscopic visualization of 
EXOGp120 and EXOOVA.  
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5.2.4 Gp120-aTexo vaccine stimulates a primary immune response in vivo  
Gp120-aTexo vaccine was prepared by co-culturing CD8+ aT cells with EXOGp120 
as described previously (150). Gp120-aTexo cells were injected IV into wild-type mice to 
assess their immunostimulatory capacity. CD8+ aT cell- or PBS-injected mice were used 
as negative controls. As no H2-Kb epitope of Gp120 has been characterized, Gp120-
specific tetramer testing is not currently available to detect proliferated Gp120-specific 
CD8+ T cells in wild-type mice. Hence, immune response was analyzed in peripheral 
blood on day 6 by analyzing the expression of activation marker CD44 or Gp-120-
specific IFN-!-expressing CD8+ T cells out of total CD8+ T cell population as described 
by Shedlock et al. (174). The IFN-! assay was performed by stimulating whole blood 
sample with cell activators, phorbol myristate acetate and calcium ionophore, and then 
cells were stained for intracellular IFN-! cytokine expression. Stimulation with cell 
activators helped to assess the degree of vaccine-induced IFN-!-secreting cells in 
comparison to the PBS or CD8+ aT control groups. In whole blood samples, the 
lymphocyte population was gated based on forward and side scatter properties and used 
for the analysis by flow cytometry. A total of 0.2 X 106 cells (events) were used for 
analysis in each sample in CD44 activation marker and IFN-! interacellular assay,. Flow 
cytometry profiles are presented as dot-scatter plots. Experiment was performed twice, 
each of which contained 4 mice per test group. For statistical analysis, the values of both 
first and second experiments were used. Mean% ± 1 S.D (n=8) of CD44+ CD8+ T cells 
out of total T cells or IFN-!+ CD8+ T cells out of the total CD8+ T-cell population in 
DCGP120 and Gp120-aTexo groups was indicated: ** p<0.05 when compared with PBS or 
CD8+ aT-injected groups.  
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Gp120-aTexo-vaccinated mice showed a significantly increased CD44high CD8+ T 
cells (5.23  ±1 0.36) compared to CD8+ aT cell- (2.65 ±1 0.14) or PBS-injected (2.51 ±1 
0.2) mice (Figure 5.10A) out of total T cells. DC2.4Gp120 cells-injected mice also showed 
an increased CD44high CD8+ (4.9 ±1 0.29) T cells similar to the Gp120-aTexo vaccine. 
Similarly, IFN-!-secreting CD8+ T cells were significantly elevated in Gp120-aTexo- 
(3.04 ±1 0.47) and DC2.4Gp120 (2.82 ±1 0.43)-immunized mice compared to CD8+ aT- (1.7 
±1 0.31) or PBS-injected (1.51 ±1 0.26) mice (Figure 5.10B), indicating that the Gp120-
aTexo vaccine effectively induced primary Ag-specific CD8+ T-cell responses in vivo. 
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Figure 5.10 Gp120-aTexo vaccine activate naïve CD8+ T cell stimulation in vivo. 
Wild-type mice were injected IV with DC2.4Gp120 or Gp120-aTexo vaccine. On day 6, 
peripheral blood samples of immunized mice were stained with FITC-anti-CD8 Ab and 
ECD-anti-CD44+ or PE-anti-IFN-! Abs (intracellularly), and analyzed by flow cytometry. 
The scatter-dot plots are derived from a representative mouse in each group. In flow 
cytometric analysis, a total of 0.2 X 106 in lymphocyte-gated population were used for 
analysis in each sample in CD44 activation marker (A) and IFN-! secretion analysis (B),. 
In each dot-scatter plot, X-axis represents fluorescence intensity of FITC (CD8 molecule 
expression) and Y-axis represents fluorescence intensity of ECD (CD44) or PE (IFN-!). 
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The net percentage of labeled cells within the gated analysis region is presented in each 
figure. Data presented is from a single analysis of an independent experiment. 
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5.2.5 Gp120-aTexo vaccine induces efficient short- and long-term anti-tumor 
immunity 
Both short- and long-term anti-tumor immunity following Gp120-aTexo 
vaccination was assessed in wild-type mice. First, C57BL/6 mice were injected IV with 
Gp120-aTexo 4 X 106 of cells per mouse and challenged with Gp120-expressing BL6-10 
tumor cells (0.5 X 106 BL6-10Gp120 /mouse) on day 6 in experiment I or on day 30 in 
experiment II subsequent to the vaccination as shown in Table 5.2. Before tumor 
challenge, BL6-10Gp120 cells were cultured overnight in the presence of an IFN-! to 
increase pMHC-I expression (Figure 5.11A). This approach increases the chances of 
efficient peptide presentation, enabling rapid recognition and killing of target cells by 
CD8+ CTLs (175, 176). BL6-10 cells form lung tumor colonies, which are prominently 
seen as black-pigmented foci/nodules of variable size and can be easily distinguished 
from surrounding lung healthy tissue. Lung tumor colonies were counted randomly, and 
if tumor colonies were too many to count, an arbitrary value of >100 was given as 
described previously (162).    
Following tumor challenge, all mice were sacrificed on day 24 to analyze lungs 
for tumor colonies. Mice immunized with Gp120-aTexo or DC2.4Gp120 cells (0/8) were 
completely protected against tumor challenge (Figure 5.11B) in both Experiment-I and -
II (Table 5.2), further suggesting that the Gp120-aTexo vaccine can stimulate CD8+ CTL 
responses efficiently, including both effector and memory stage anti-tumor immunity. 
Histopathological analysis of lung tissue sections was showed numerous tumor nodules in 
PBS-injected mice, but not in Gp120-aTexo-injected mice. (Figure 5.11C  
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Table 5.2 Gp120-aTexo protects C57BL/6 mice against lung tumor metastases 
Immunization Tumor challenge Visible tumor 
growth incidence 
(%) 
Median number of 
lung tumor colonies 
Experiment I.    
Gp120-aTexo  BL6-10Gp120                           0/8 (0)a 0 
DC2.4Gp120 BL6-10Gp120 0/8 (0)a 0 
CD8+ aT BL6-10Gp120 8/8 (100)b >100 
PBS BL6-10Gp120 8/8 (100)b >100 
    
Experiment II    
Gp120-aTexo BL6-10Gp120 0/8 (0)a 0 
DC2.4Gp120  BL6-10Gp120 0/8 (0)a 0 
PBS BL6-10Gp120 8/8 (100)b >100 
a: Immunized group, b: control group 
In experiment I, C57BL/6 mice were injected IV with the DC2.4Gp120 (2 X 106/mouse), 
Gp120-aTexo vaccine (4 X 106/mouse), CD8+ aT cells (4 X 106/mouse) or PBS, and 
challenged with BL6-10Gp120 (0.5 X 106/mouse) tumor cells on day 6 after immunization. 
In experiment II, challenge with BL6-10Gp120 tumor cells was done on day 30 after 
immunization. All mice were sacrificed on day 24 after tumor challenge, and the lungs 
were examined for the number of black tumor colonies.  
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Figure 5.11 Gp120-aTexo vaccine induces short- & long-term anti-tumor immunity. 
A) BL6-10Gp120 cells were cultured in the presence of IFN-! (20 ng/ml) to augment the 
expression of pMHC-I. (B and C). In the tumor protection study, Gp120-aTexo- and 
DC2.4Gp120-immunized mice showed complete protection against lung metastasis as 
confirmed by both gross analysis (B) and histopathological studies (C), PBS-injected 
mice developed numerous tumor nodules (arrows) whereas the Gp120-aTexo-injected 
mice lungs were devoid of visible tumor nodules.  
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PART C  
5.3 Gp120-aTexo vaccine induces primary and memory CD8+ CTL 
responses and anti-tumor immunity in A2-Kb transgenic mice. 
5.3.1 Characterization of recombinant AdVGp120  
After successful AdVGp120 construction and amplification, samples were analyzed 
to determine the expression of the gene of interest and protein synthesis by PCR and 
western blot, respectively. Both PCR and western blot analysis confirmed Gp120 gene 
insertion (Figure 5.12C) and efficient protein expression (Figure 5.12D) by the purified 
AdvGp120 stock.  
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Figure 5.12 Characterization of the recombinant AdV vector. AdvGp120 recombinant 
plasmid was generated using pShuttleCMV and pAdEasy AdV vector systems, and the 
virus particles were produced and amplified in HEK-293 cells. A) Transfection efficiency 
of the lipofectamine-2000 method in HEK-293 cells was checked using pmax-GFP as a 
transfection control. B) Cytopathic-effect in HEK-293 cells induced by AdV 
multiplication. C) PCR and D) western blot analysis for the characterization of Gp120 
insertion and Gp120 expression by the purified AdVGp120, respectively. 
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5.3.2 Characterization of BL6-10Gp120 tumor cells transfected with A2-Kb  
A2-Kb transgenic mouse model is a well-recognized murine model used to 
investigate recognition of Ag epitopes in the context of HLA-A2 (177, 178). This is 
because A2-Kb transgenic mice contain MHC class-I molecules composed of "1 and "2 
domains of HLA-A2, and ß-microglobulin, trans-membrane and cytoplasmic domains 
derived from H2-Kb mice (179-181). Many studies have shown that the "1 and "2 
domains of MHC-I have a decisive role in MHC-I-specific CD8+ T cell repertoire 
selection. Upon immunization, these transgenic mice develop A2-Kb-restricted CTL 
responses to the antigenic epitope which is also an immuno-dominent epitope in a HLA-
A2-restricted environment (181). Therefore, the A2-Kb transgenic mouse model serves as 
an excellent model system for HLA-restricted immune response studies.  
Hence, in the present study, the Gp120-aTexo vaccine immunotherapeutic effect 
was evaluated using a tumor protection study in A2-Kb transgenic mice. BL6-10Gp120 
tumor cells were transfected with the A2-Kb. In this way, BL6-10 tumor cells were able to 
express Gp120 epitopes on HLA-A2 molecules as required to test the efficacy of the 
Gp120-aTexo vaccine in A2-Kb transgenic mice. The potential positive transfected clones 
were analyzed by flow cytometry where they showed HLA-A2 expression on cell surface 
(Figure 5.13B). 
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Figure 5.13 Characterization of BL6-10Gp120 tumor cells transfected with A2-Kb. 
BL6-10Gp120 tumor cells were transfected with pcDNA-A2-Kb vector. A) pmax-GFP-
transfected BL6-10Gp120 cells were used as transfection controls to monitor transfection 
efficiency. B) Clones grown under selective drug pressure were confirmed for the 
expression of HLA-A2 protein by flow cytometry by staining with HLA-A2 Abs (solid 
thick lines). An irrelevant isotype-matched Ab was used as a control (dotted thin lines). 
In figure, X-axis represents histograms of fluorescence intensity (log10) of FITC (HLA-
A2 expression) and Y-axis represents the relative number of tumor cells. A total of 5000 
events were used for analysis for each marker. Data presented are from a single analysis 
of an independent experiment.  
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5.3.3 AdVGp120-transduced BMDCs and released EXOs express maturation and 
immune-stimulatory molecules 
AdvGp120 contains a RGD-modified fiber domain, which enhances AdV infection 
and transgene expression in BMDCs. The RGD-fiber-modified AdV shows of transgene 
expression in >80% BMDCs at a MOI of 150 (125). DCs transduced with AdVGp120 to 
achieve transgene expression were termed as DCGp120. EXOs released from these cells 
were called EXOGp120. Mature AdvGp120-infected DCs derived from A2-Kb mice and their 
EXOs were characterized by flow cytometry for different surface marker expression with 
a panel of Abs. The results indicated that A2-Kb-derived DCGp120 express both maturation 
and activation markers (HLA-2, Iab, CD11c, CD54, CD80 & CD86) (Figure 5.14), 
suggesting a potent Ag-presenting and immuno-stimulatory capacity. EXOGp120 also 
showed the expression of maturation and activation markers, which is consistent with 
previous results (150, 151). 
In flow cytometry analysis, DC population was gated based on FSC and SSC dot 
plots and used to obtain histogram fluorescence (FITC) on FL1 channel. A total of 30,000 
and events of DC or EXO, respectively, were analyzed for each marker. DCOVA and 
EXOOVA were analyzed in flow cytometry every time when they were prepared (at least 3 
times) to verify the quality of purification. 
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Figure 5.14 Phenotypic characterization of DCGp120 and EXOGp120. Mature DCGp120 or 
EXOGp120 were stained with a panel of FITC-conjugated Abs specific for DC maturation 
markers, MHC class I and II molecules, and other DC-specific markers (solid thick line) 
with irrelevant isotype-matched Ab controls (dotted thin line), and analyzed by flow 
cytometry. In each figure, X-axis represents histograms of fluorescence intensity (log10) 
of FITC (analyzed for HLA-A2, Iab, CD11c, CD54, CD80 and CD86 expression) and Y-
axis represents the relative number of DCs or EXOs. A total of events were used for 
analysis for each marker. Data presented are from a single analysis of an independent 
experiment.  
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5.3.4 ConA CD8+ aT cells acquire and express exosomal molecules 
ConA CD8+ aT cells were purified using anti-mouse CD8+ paramagnetic micro-
beads (Miltenyi Biotec) by positive selection, which gave >90% purity (Figure 5.15A). 
Previously, a protocol has been established for optimal exosomal molecule acquisition by 
activated T cells (151). To produce Gp120-aTexo cells, CD8+ aTcells were co-cultured 
with EXOGp120 in the presence of IL-2 for 5 hr. Unstimulated CD8+ T cells, CD8+ aT cells 
and Gp120-aTexo cells were stained with a panel of Abs specific for CD8+ T cell 
activation and DC maturation markers and analyzed by flow cytometry. The results 
indicate that CD8+ aT cells acquired the exosomal molecules and present them on their 
surface (Figure 5.15B). In comparison with ConA CD8+ aT cells, increased CD80 
molecules on Gp120-aTexo cells clearly suggest the transfer of exosomal proteins, such 
as immunostimulatory molecules, on to active CD8+ T cells. In flow cytometric analysis, 
lymphocyte population was gated and used to obtain histogram of fluorescence of FITC 
on FL1. A total of 30,000 events of unstimulated CD8+ T, CD8+ aT or Gp120-aTexo 
were used for analysis for each marker. Gp120-aTexo cells were analyzed in flow 
cytometry at least 3 times, and data presented below are from a single analysis of an 
independent experiment. 
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Figure 5.15 ConA CD8+ aT cells up-take and express exosomal molecules. A) CD8+ T 
cells purified from ConA-activated T cells by positive selection show >90% purity. The 
net percentage of labeled cells within the gated analysis region is presented in the figure. 
B) Naïve CD8+ T, CD8+ aT, and Gp120-aTexo cells were stained with a panel of Abs 
specific for mature DC and CD8+ aT cell (solid thick lines) markers, and compared with 
irrelevant Ab isotype-matched controls (dotted thin lines) by flow-cytometry. In each 
figure, X-axis represents histograms of fluorescence intensity (log10) of FITC (analyzed 
for CD8, HLA-A2, Iab, CD25, CD40L and CD80 expression) and Y-axis represents the 
relative number of CD8+ aT or OVA-aTexo cells. A total of 30,000 events of CD8+ aT or 
Gp120-aTexo were used for analysis for each marker. Gp120-aTexo cells were analyzed 
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in flow cytometry at least 3 times, and data presented above are from a single analysis of 
an independent experiment.  
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5.3.5 Gp120-aTexo vaccine stimulates proliferation of Ag-specific CD8+ T cells 
To assess the immuo-stimulatory effect of Gp120-aTexo vaccine in A2-Kb 
transgenic mice, blood samples were collected on day 6 after immunization. Blood 
samples were subjected to CD44 marker expression analysis and intracellular IFN-! 
cytokine assay to detect vaccine-stimulated Gp120-specific CD8+ T cells as described in 
Bolesta et al. (182). The tetramer assay was performed as described previously using PE-
conjugated HLA-A2/Gp120121-129 (KLTPLCVTL) (167, 168) reagent, which is specific 
for the T cell receptor of Gp120-specific CD8+ T cells in A2-Kb mice.  
Following immunization of A2-Kb mice with 4 X 106 Gp120-aTexo cells, or 2 X 
106 DCGP120, the proliferated CD44high, tetramer+ and IFN-!+ CD8+ T cells in peripheral 
blood were monitored on day 6. In whole blood samples, the lymphocyte population was 
gated and used for the analysis by flow cytometry. A total of 0.2 X 106 cells (events) were 
used for analysis in each sample. Flow cytometry profiles are presented as dot-scatter 
plots. Experiment was performed twice, each of which contained 4 mice per test group. 
For statistical analysis, the values of both first and second experiments were used. 
Mean% ± 1 S.D (n=8) of CD44high CD8+ T cells, Gp120-specific tetramer+,or IFN-!+ 
CD8+ T cells out of the total CD8+ T cell population in DCOVA or OVA-aTexo groups 
was indicated: ** p<0.05 when compared with PBS or CD8+ aT-injected groups.  
Gp120-aTexo- and DCGp120-immunized groups contained an average of 4.71% ±1 
0.48 and 5.85% ±1 0.53 CD44+CD8+ cells out of total T cells, 3.55% ±1 0.38 and 4.89% 
±1 0.41 of Gp120-specific tetramer+ CD8+ T cells out of total CD8+ T cells, and 3.12% ±1 
0.31 and 3.77% ±1 0.55 of IFN-!+ Gp120-specific CD8+ T cells out of total CD8+ T cells, 
respectively (Figure 5.16). These results strongly suggest that Gp120-aTexo vaccine is 
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capable to induce Gp120-specific CD8+ T-cell proliferation in vivo similar to that induced 
by DCGp120.  
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Figure 5.16 Gp120-aTexo vaccine induces efficient Ag-specific CD8+ T-cell 
proliferation in vivo. A2-Kb transgenic mice were injected IV with PBS, CD8+ aT, 
Gp120-aTexo or DCGp120. On day 6 post immunization, peripheral blood was collected 
and stained with PE-HLA-A2/Gp120(121-129), PE anti-CD44 or PE anti-IFN-!, and FITC-
anti-CD8+ Abs, and analyzed by flow cytometry. The scatter-dot plots are derived from a 
representative mouse in each group on day 6 post immunization. In flow cytometric 
analysis, a total of 0.2 X 106 cells in lymphocyte-gated population were used for analysis 
in each sample. In each dot-scatter plot, X-axis represents fluorescence intensity of FITC 
(CD8 molecule expression) and Y-axis represents fluorescence intensity of PE (IFN-! or 
Gp120-specific tetramer) or ECD (CD44). The net percentage of labeled cells within the 
gated analysis region is presented in each figure. Data presented is from a single analysis 
of an independent experiment. 
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5.3.6 Phenotypic characterization of Gp120-aTexo-stimulated CD8+ effector CTLs 
To further characterize the phenotype of Gp120-specific CD8+ T cells, peripheral 
blood was collected from Gp120-aTexo- or DCGp120-immunized mice on day 7 and 
processed for triple staining. Ag-specific CD8+ T cells in both groups immunized with 
Gp120-aTexo and DCGp120 showed expression of activation markers such as CD44 and 
CD69, but not memory markers, such as CD62L, IL-7R! and CCR-7, suggesting effector 
CTL phenotype (Figure 5.17).  
In whole blood samples, the lymphocyte population was gated based on forward 
and side scatter properties and used for the analysis by flow cytometry. A total of 0.5 X 
106 cells (events) were used for analysis in each sample of primary immune response 
study (Results 5.3.5). To see the expression of specific markers on proliferated Gp120-
specific CD8+ T cells, tetramer and CD8 double positive cells were gated to obtain 
histogram fluroscence on FL3 (ECD). Experiment was performed twice wherein blood 
from different animals of each group was pooled, stained for different markers and 
analyzed. 
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Figure 5.17 Phenotypic characterization of Gp120-specific CD8+ CTLs. On day 7, 
peripheral blood samples from immunized mice were stained with PE-HLA-
A2/Gp120121-129 tetramer and FITC-CD8 Ab along with a panel of biotin-labeled Abs 
specific for effector or memory T cells markers, and streptavidin-PE-Texas Red (ECD), 
and then analyzed by flow cytometry. In each histogram figure, X-axis represents 
histograms of fluorescence intensity (log10) of ECD (conjugated to CD44, CD62L, CD69, 
CCR7, or IL-7R! expression) and Y-axis represents the relative number of tetramer and 
CD8 double positive cells. Data presented are from a single analysis of an independent 
experiment. 
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5.3.7 Gp120-aTexo-stimulated effector CD8+ T cells have cytotoxic activity 
To further analyze effector functions of the Gp120-specific CD8+ T cells, an in 
vivo cytotoxicity assay was performed in above mice (used in section 5.3.5) as described 
previously (164). The data is presented as mean% ± 1 S.D (n=8) of Gp120-specific CD8+ 
T cells out of the total CD8+ T cell population in DCGP120 or Gp120-aTexo group: ** 
p<0.05 when compared with PBS or CD8+ aT-injected groups. For statistical analysis, the 
values of both first and second experiments with four mice per group were used. Due to 
an efficient cytotoxic response, significant lysis of CFSEhigh-labeled target cells was 
observed in Gp120-aTexo and DCGp120-immunized mice (Figure 5.18). An average of 
25% ±1 5.6 and 20% ±1 4.7 of residual target cells were observed in A2-Kb mice 
immunized with Gp120-aTexo and DCGp120, respectively. On the other hand, no such 
cytotoxic activity was observed in PBS- or CD8+ aT-injected mice.  
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Figure 5.18 Gp120-aTexo vaccine stimulates CD8+ T-cell differentiation into effector 
CTLs. Immunized mice were adoptively transferred on day 7 with 1:1 ratio of 
splenocytes labeled with high (3.0 M, CFSEhigh) and low (0.6 M, CFSElow) CFSE-pulsed 
with Gp120 and Mut1 peptide, respectively. After 16 hr, the residual CFSEhigh (target) 
and CFSElow (control) cells remaining in the spleens were determined in the immunized 
mice by flow cytometry. In each figure, X-axis represents histograms of fluorescence 
intensity (log10) of CFSElow and CFSEhigh and Y-axis represents the relative number of 
labeled cells. An average of 1,000 labeled cells were analyzed by flow cytometry for each 
sample. The values in each figure represent the residual CFSEhigh and CFSElow cells 
remaining in the spleen. Data presented is from a single analysis of an independent 
experiment.  
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5.3.8 Gp120-aTexo vaccine stimulates an efficient Ag-specific memory response 
In another experiment, the presence of Ag-specific memory cells was studied in 
Gp120-aTexo- and DCGp120-injected mice. On day 30 after immunization, peripheral 
blood samples from Gp120-aTexo- and DCGp120-immunized mice were analyzed using 
tetramer assay to determine the percentage of Gp120-specific CD8+ T cells before tumor 
challenge. In the analysis, an average of 0.54% ±1 0.08 and 0.81% ±1 0.12 of tetramer-
positive cells were observed in Gp120aTexo- and DCGp120-injected groups, respectively 
(Figure 5.19A). These are T memory cells specific for Gp120 protein after 
immunization. To confirm whether tetramer-positive cells are memory cells, these cells 
were phenotypically characterized on day 30 for the expression of memory markers. The 
flow cytometry analyses showed the expression of memory markers, such as CD44, 
CD62L, CCR7 and IL-7R!, in tetramer-positive cells (Figure 5.19B), suggesting that 
these cells are transformed long-lived T memory cells (183).  
In whole blood samples, the lymphocyte population was gated and used for the 
analysis by flow cytometry. A total of 0.5 to 0.8 X 106 cells (events) were used for 
analysis in each sample. To see the expression of specific markers on proliferated Gp120-
specific CD8+ T cells, tetramer and CD8 double positive cells were gated to obtain 
histogram fluroscence on FL3 (ECD). Experiment was performed twice wherein blood 
from different animals of each group were pooled, stained for different markers and 
analyzed. 
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Figure 5.19 Phenotypic characterization of Ag-specific memory T cells. A) On day 30 
after Gp120-aTexo or DCGp120 injection, blood samples were collected and stained with 
PE-HLA-A2/Gp120121-129 tetramer and FITC-CD8 Ab. The scatter-dot plots are derived 
from a representative mouse in each group on day 6 post-immunization. In flow 
cytometric analysis, a total of 0.5 to 0.8 X 106 cells in lymphocyte-gated population were 
used for analysis in each sample. In each dot-scatter plot, X-axis represents fluorescence 
intensity of FITC (CD8 molecule expression) and Y-axis represents fluorescence 
intensity of PE (Gp120-specific tetramer). The net percentage of labeled cells within the 
gated analysis region is presented in each figure. Data presented is from a single analysis 
of an independent experiment. B) Phenotypically characterized tetramer and CD8 double 
positive cells using a panel of biotin-labeled Abs specific for effector or memory 
markers, and streptavidin-PE-Texas Red (ECD) (solid thick lines). Tetramer and CD8 
double positive cells stained with irrelevant isotype-matched Abs were used as controls 
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(dotted thin lines). In each figure, X-axis represents histograms of fluorescence intensity 
(log10) of ECD (analyzed for CD44, CD62L, CD69, CCR7, and IL-7R! expression) and 
Y-axis represents the relative number of tetramer and CD8 double positive cells. Data 
presented are from a single analysis of an independent experiment. 
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5.3.9 Gp120-aTexo vaccine induces efficient short- and long-term anti-tumor 
immunity 
The efficacy of Gp120-aTexo vaccine in inducing functional effector and memory 
CD8+ CTLs was studied using a tumor protection approach. A2-Kb mice were injected IV 
with DCGp120, Gp120-aTexo vaccine, CD8+ aT cells or PBS, and challenged with BL6-
10Gp120/A2-Kb tumor cells on day 6 after immunization in experiment I, and on day 30 
after immunization in experiment II (Table 5.3). Before tumor challenge, BL6-
10Gp120/A2-Kb cell were cultured overnight in the presence of IFN-! to enhance pMHC-I 
expression. All mice were sacrificed on day 24 after tumor challenge, and the lungs were 
observed for the black tumor colonies. 
In both experiment-I and –II, results showed that the mice which received Gp120-
aTexo or DC2.4Gp120 cells were completely protected with no tumor colonies 
development for 24 days from tumor challenge, whereas PBS- or CD8+ aT-injected mice 
showed development of black-pigmented tumor colonies in their lungs (Figure 5.20; 
Table 5.3), suggesting Gp120-aTexo vaccine can stimulate CD8+ CTL responses capable 
of inducing anti-tumor immunity both during effector and memory stage. Experiment was 
performed twice each with 8 mice per group. After immunization, 4 mice in each group 
were used for the effector-stage anti-tumor immunity study, whereas another 4 mice were 
used for the memory-stage anti-tumor immunity.  
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Table 5.3 Gp120-aTexo vaccine protects A2-Kb mice against lung tumor metastases 
during effector and memory stage 
Immunization Tumor challenge 
Visible tumor 
growth incidence 
(%) 
Median number of 
lung tumor colonies 
Exp. I.    
Gp120-aTexo  BL6-10Gp120/A2-Kb 0/8 (0)a 0 
DCGp120 BL6-10Gp120/A2-Kb 0/8 (0) a 0 
CD8+ aT BL6-10Gp120/A2-Kb 8/8 (100)b >100 
PBS BL6-10Gp120/A2-Kb 8/8 (100) b >100 
    
Exp. II    
Gp120-aTexo BL6-10Gp120/A2-Kb 0/8 (0) a 0 
DCGp120  BL6-10Gp120/A2-Kb 0/8 (0) a 0 
CD8+ aT BL6-10Gp120/A2-Kb 8/8 (100)b >100 
PBS BL6-10Gp120/A2-Kb 8/8 (100)b >100 
a: Immunized group, b: control group 
A2-Kb mice were injected IV with DCGp120, Gp120-aTexo vaccine, CD8+ aT cells or 
PBS, and challenged with BL6-10Gp120/A2-Kb tumor cells on day 6 post-immunization in 
experiment I, and on day 30 post-immunization in experiment II. All mice were sacrificed 
on day 24 after tumor challenge, and the lungs were examined for the number of black 
tumor colonies. Values in the table are cumulative of two independent experiments with 
four mice per group. 
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Figure 5.20 Gp120-aTexo vaccine induces both effector and memory anti-tumor 
immunity. Gp120-aTexo, DCGp120, CD8+ aT or PBS were injected IV into A2-Kb mice. 
The mice were later challenged with BL6-10Gp120/A2-Kb tumor cells. The Gp120-aTexo- 
and DCGp120-immunized groups showed complete protection against lung tumor colonies 
formation. Lungs from one mouse/group in one of two independent experiments are 
shown.  
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PART D  
5.4 Gp120-aTexo vaccine possesses a therapeutic effect when injected 3- 
or 6-day post challenge on the establishments of lung tumors in A2-Kb 
transgenic mice  
This study examined the therapeutic efficacy of Gp120-aTexo vaccine in A2-Kb 
transgenic mouse model by employing a tumor challenge study (BL6-10Gp120/A2-Kb). 
A2-Kb mice were challenged with BL6-10Gp120/A2-Kb melanoma tumor cells, and 
immunized with Gp120-aTexo cells on 3 or 6 days after tumor challenge as presented in 
the Table 5.4. All mice were sacrificed on day 24 after tumor challenge, and the lungs 
were examined for the number of black-pigmented tumor colonies. 
In the results, 100% (8/8) and 75% (2/8) of Gp120-aTexo-injection A2-Kb mice 
were protected from lung tumor metastases in experiment I and II, respectively. Mice 
injected with PBS showed 0% protection in both experiments (Table 5.4). These results 
indicate that Gp120-aTexo vaccine has the potential to eradicate tumor cells early after 
their engraftment, suggesting a possible therapeutic effect for the vaccine. Experiment 
was performed twice each with 8 mice per group. After tumor challenge, 4 mice in each 
group were used for immunization on day 3, whereas another 4 mice were used for 
immunization on day 6.  
. 
 
 
 
 
! "#+!
Table 5.4 Therapeutic efficacy of Gp120-aTexo vaccine in a melanoma tumor model 
Animal groups Tumor challenge Injection IV 
Tumor 
growth 
incidence 
(%) 
Median 
number of 
lung 
tumors 
colonies 
Exp. I. (Day -3)     
Test group BL6-10Gp120/ A2-Kb Gp120-aTexoa 0%  (0/8) 0 
Control group BL6-10Gp120/ A2-Kb PBSb 100% (8/8) >100 
     
Exp. II (Day -6)     
Test group BL6-10Gp120/A2-Kb Gp120-aTexoa 25% (2/8) 19±6 
Control group BL6-10Gp120/ A2-Kb PBSb 100% (8/8) >100 
a: Immunized group, b: control group 
In experiment-I and -II, mice were immunized with Gp120-aTexo vaccine 3 or 6 days 
after tumor challenge, respectively. Mice were sacrificed 24 days after tumor challenge 
and the number of lung tumor colonies was determined.! Values in the table are 
cumulative of two independent experiments with four mice per group. !!!!!!!!!!!
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CHAPTER 6 
DISCUSSION  
Immuno-suppression is a hallmark of HIV-1 infection. Continuous replication of 
HIV-1 in CD4+ T cells leads to the depletion of the CD4+ T cell population in the body. 
DCs are also targets for this virus since the virus infects DCs through C-type lectin and 
DC-SIGN receptors gradually rendering these cells dysfunctional or tolerogenic. 
Continuous exposure of DCs to HIV-1 envelope proteins, particularly to Gp120, leads to 
the incomplete activation of DC. These incompletely activated DCs secrete more IFNs 
and indoleamine 2,3 dioxygenase, but less IL-12 (59, 60). Due to less DC-derived IL-12, 
CD4+ T cells are not stimulated, resulting in a CD4-derived IL-2 signal deficiency.  As a 
result, HIV-1-specific CD8+ CTL activation and differentiation occurs less efficiently. 
Consequent to these negative effects, the affected individual’s immune system becomes 
susceptible to many opportunistic diseases.  
Currently available HIV-1 vaccines such as killed, attenuated or subunit, were 
failed to induce a therapeutic immune response to HIV-1. Live attenuated HIV-1 vaccines 
have been shown to revert to their pathogenic forms (95, 96). Inactivated HIV-1 vaccines 
fail to induce effective immune responses in primates, perhaps due to the of CD4+ T cell 
deficiency (98).  
In search of a novel therapeutic vaccine designed to stimulate immune cells 
compromised by HIV infection and in view of the limitations of existing therapeutic 
vaccine strategies, this study developed a T cell-based CD8+aTexo vaccine.  The 
CD8+aTexo vaccine stimulates the immune response through acquired Ag-presenting 
molecules and co-stimulatory molecules (in a CD4+ T cell-independent manner).  The 
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CD8+aTexo vaccine was assessed for its preventive and therapeutic efficacy in both wild 
type (C57BL/6) and humanized (A2-Kb) mouse models using a melanoma challenge 
model.     
In this study, the DC2.4 cell line (184) was used as a substitute for BMDC since it 
is cost effective and time saving. Using this cell line reduces the costs associated with the 
use of cytokines, such as GM-CSF, IL-4 and TNF-!, and the time needed for generating 
mature BMDC, which generally takes 7 days. The DC2.4 cell line (immature status) does 
not express maturation markers; therefore, the maturation of this cell line was induced by 
culturing with IFN-!. IFN-! is known to up-regulate the expression of class-I and -II 
MHC, CD40, CD80 and CCR7 in this cell line (184).  
To generate Gp120-aTexo several components were created and are detailed in 
the Results Section. DC cell line (DC2.4) and B16 melanoma cell line (BL6-10) were 
transfected with Gp120 to generate DC2.4Gp120 and BL6-10Gp120, respectively. EXO-
targeted T cell vaccines (OVA-aTexo or Gp120-aTexo) were prepared by incubating 
ConA CD8+ aT cells with EXOOVA or EXOGp120. Immunization of wild-type mice with 
OVA-aTexo resulted in the induction of OVA-specific CD8+ T cell effector and memory 
responses. Gp120-aTexo vaccine was also able to provide both preventive and 
therapeutic efficacy against Gp120-expressing BL610 melanoma challenge in wild-type 
mice.   
  DC-derived exosomes appear to be the key factor behind the stimulatory power of 
the aTexo vaccine. EXOs may mediate the immune response in vivo by either or both of 
two potential pathways: a) up-take of EXO by immature DC; and b) up-take of EXO by 
activated T cells. These EXO molecule up-take pathways might stimulate CD8+ T cell 
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responses (185). DC-secreted EXOs express Ag-presenting molecules and co-stimulatory 
molecules (156, 157) and in association with immune cell types, especially DCs and 
activated T cells, they stimulated effector and memory CTL responses capable of 
protecting host against tumor challenge (149, 186, 187). In a murine model, when tumor-
derived EXOs expressing tumor-specific peptides on MHC-I molecules were loaded onto 
mature DCs and injected into mice, strong CD8+ CTL responses leading to regression of 
tumor growth were observed (138). Recently, in one human clinical trial, EXOs purified 
from the ascites fluid of cancer patients were loaded on to mature DCs and reintroduced 
to the patients, resulting in regression of tumors in skin and lymph nodes (148).    
Previously, Hoa et al. (150) demonstrated that a CD4+aTexo vaccine was able to 
stimulate OVA-specific CD8+ CTL responses and elicit antitumor immunity more 
efficiently as compared to EXOOVA or DCOVA alone (150). Furthermore, it was shown 
that such a stimulatory function is mediated through secretion of IL-2, CD40L and CD80 
signaling, and acquired pMHC-I molecules (188). In support of this, CD4+ T cells 
acquiring pMHC-I and CD80 and CD86 co-stimulatory molecules from DCs, in the 
process of DC Ag-presentation and stimulation of T cells, have been shown to induce Ag-
specific T cell responses by up-regulating NF-kB and Stat5 signaling molecules (189). 
Perhaps due to these reasons, CD4+aTexo vaccine induces OVA-specific CD8+ T cell 
responses independent of CD4+ T cell help (150, 165). T regulatory cells are a 
subpopulation of T cells which induce immuno-suppression or tolerance by suppressing 
immune activation to self Ags (190, 191). Interestingly, the CD4+aTexo vaccine 
stimulated CD8+ central memory CTL responses in the presence of CD25+ T regulatory 
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cells (151), indicating this vaccine can break T regulatory cell-mediated immune 
tolerance.    
 In line with previous results, this thesis demonstrates that non-specific ConA 
CD8+ aT cells can also take up DCOVA-released EXOs and express exosomal derived 
immunologically important molecules (Ag-presenting machinery and co-stimulatory 
molecules) on their surfaces, leading to development of the OVA-aTexo vaccine (138). In 
support of my hypothesis, the OVA-aTexo vaccine was able to induce both short- and 
long-term Ag-specific CD8+ T cell responses and anti-tumor immunity independent of 
host DC and CD4+ T cell help (192). Furthermore, the present study demonstrated that 
the stimulatory power of OVA-aTexo vaccine was mainly mediated through acquired 
pMHC-I complexes, which might interact with Ag-specific naive CD8+ T cell receptor 
(signal-1), CD40L co-stimulation (signal-2) and IL-2 cytokine signal (signal-3), which is 
known to provide survival signals or act as growth factor for the expansion of CD8+ aT 
cells (150). From these results, it appears both CD4+aTexo and CD8+aTexo vaccines 
follow similar mechanisms to induce efficient CD8+ T cell responses.   
 Macaque monkeys with SIV infection are considered to be an excellent non-human 
primate model for HIV-1 pathogenesis study. Both HIV and SIV are closely related at the 
molecular level, in pathology and viral replication. However, several limitations are 
associated with the SIV model, such as cost, accredited primate facilities and differences 
in the rate of disease progression. Mouse models were proposed for studying HIV 
infection and vaccine studies, as these are more appealing for many reasons, including 
low cost, quick reproduction, and easy manipulation and handling. HIV-1 is normally 
non-infectious for mice (193). Therefore, murine models for HIV-1 infection involve 
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mice reconstituted with a human immune system either partially or in whole. In the 
second part of this thesis research, AdVGp120-infected DCs were used to generate 
EXOGp120. These EXOGp120 were then co-cultured with spleen-derived ConA CD8+ aT 
cells to prepare a Gp120-aTexo vaccine. Vaccine efficacy was tested in A2-Kb transgenic 
humanized mice, which express "1 and "2 domains of HLA-A2 (forms antigenic peptide 
binding cleft of human class-I MHC). These A2-Kb mice allow studies of adaptive 
cellular immunity (Class I Ag presentation and CD8+ CTL responses) in the context of a 
human Ag presentation (194).  In addition, the tetramer reagent is available for 
quantifying Gp120-specific CD8+ CTLs in HLA-A2 background; therefore, the number 
of CD8+ CTLs can be easily assessed after immunization of A2-Kb mice. It has been 
shown that the Gp120-specific CD8+ T cells in A2-Kb mice are similar to those found in 
humans in terms of their epitope specificity (195). 
 Several factors could explain this stimulatory power of the Gp120-aTexo vaccine. 
AdVs are known to provide the strong toll like receptor signaling required for maturation 
of DC and expression of co-stimulatory molecules (134, 165). Previously, Rea et al. and 
Hirschowitz et al. (196, 197) showed that AdV infection of DCs activates and increases 
the expression of maturation markers (MHC class-II, CD54) and co-stimulatory 
molecules (CD40, CD80, CD86). Similarly, Miller et al. (198) reported that AdV 
infection of DCs up-regulated the expression of immuno-stimulatory molecules compared 
to immature DCs. It was also demonstrated that AdV induces maturation of DCs via P13-
kinase and involved TNF-! mediated signaling pathways of NF-kB activation (199, 200). 
This evidence together suggests AdV-stimulated DCs express higher levels of maturation 
and co-stimulatory molecules, and secreted EXOs expressing increased levels of Ag-
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presenting machinery. In the preparation of Gp120-aTexo vaccine, high concentration of 
EXOs was used (10 µg EXO/1 X 106 CD8+ aT cells). This high concentration might 
result in the increased expression of Ag-presenting molecules on CD8+ aT cells. Thus, the 
increased levels of Ag-presenting molecules on Gp120-aTexo cells might have 
contributed to the increased CD8+ CTL responses after immunization.  
Many studies have shown that administration of activated T cells can result in 
immuno-regulatory effects. Hong et al. (201) reported immuno-suppression after 
injection of irradiated T cells in patients with multiple sclerosis. Kishimoto et al. (202) 
showed suppression of experimental autoimmune disease in mice when they were 
injected with myelin-basic-protein-reactive autologous T cells. Two other important 
studies by Hao et al. (150, 151) contradicted, these T cell-related immuno-regulatory 
effects.  These studies showed that CD4+ aT cells, which acquired OVA-specific EXO 
induce Ag-specific immune responses. My thesis research also showed in two different 
animal models, that Gp120-aTexo vaccine can stimulate efficient immune responses to 
Gp120-HIV-1-specific protein. The discrepancy in the results of these studies could be 
due to the nature of the T cells and the immunogen used for vaccine preparation. It has 
been confirmed that irradiation induces considerable apoptosis of T cells, and the 
apoptotic bodies have been shown to induce immuno-suppression by activating T 
regulatory cells. On the other hand, in the present study, IL-2-secreting ConA CD8+ aT 
cells and EXOs as immunogen were used in the vaccine preparation. The peptide form of 
Gp120 in the EXOs appeared to be safer than using whole Gp120, which has shown to 
have inhibitory effects on T cells, B cells and DCs function. Indeed, previously CD4-
independent functional CD8+ T cell responses were observed when an AdV-encoded 
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lymphocytic choriomeningitis virus-derived epitope was used rather than full-length 
protein to induce immune responses (203). Similarly, another study also showed the 
generation of CD8+ CTL responses to tumor in the absence of CD4+ T cells help by using 
a high-concentration of peptide-pulsed DCs for immunization (204). These studies could 
explain why aTexo vaccines induce CD4-independent CTL responses.  
Many studies have already demonstrated the pivotal role of CD8+ T cells in 
controlling established HIV-1 infection. Schmitz et al. (82) demonstrated the importance 
of CD8+ T cells in controlling SIV infection in macaque monkeys. When CD8+ T cells 
were depleted in chronically SIV-infected macaque monkeys, the viral burden increased.  
Reconstitution of CD8+ T cells, which reappear later in the lymph nodes and peripheral 
blood, led to a decline in the viral load suggesting the importance of CD8+ T cells in 
halting viral replication. A study on HIV-1 patients also suggested that CD8+ T cell 
responses can reduce viral load in plasma for more than 20 years without HAART 
therapy (46). These studies emphasize the importance of therapeutic vaccines in the 
control of HIV-1 infection since these vaccines may delay patients’ anti-retroviral 
therapy. Gp120-aTexo vaccine effectively eradicated the early- and late established lung 
tumor colonies in A2-Kb mice, suggesting its therapeutic utility. Chronic diseases such as 
HIV and cancers follow similar immunological responses. For instance, both of these 
disease types are known to induce immuno-suppression and T cell exhaustion. Hence, 
Gp120-aTexo vaccine could efficiently induce CTL responses even in chronic diseases 
such as HIV in the presence of tolerance and the absence of CD4+ T cells.    
Anti-retroviral drugs reduce HIV-1-related morbidity and mortality. Indeed, 
HAART preserves HIV-1-specific CD4+ T cells by controlling HIV replication in the 
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early period of the treatment (205). However, this treatment has adverse effects on 
patients’ health, which reduces their life quality (206). Previously, several therapeutic 
vaccines used on patients under HAART therapy have shown to decrease the dose of the 
drug administration and prolonged their lives (207, 208). Based on these results, it is 
possible that Gp120-aTexo vaccine can act as an excellent adjunct to HAART therapy, 
especially during established infections. Current and previous evidence on aTexo vaccine 
studies suggest Gp120-aTexo vaccine might induce CD8+ T cell responses in HIV 
patients without CD4+ T cells and DCs help. Therefore, Gp120-aTexo vaccine could be 
useful at any stage of the infection.  
 It is clearly understood that development of a protective vaccine, which induces 
neutralizing Ab production, is difficult during HIV-1 infection. Consequently, newer 
approaches that induce T cell responses are being evaluated or are under development. 
The rationale is that the cellular immune response can control HIV-1 replication through 
destruction of infected host cells thereby controlling disease progression. Collectively, 
although further in depth study and characterization is required to consider their use in 
humans, the present results suggest that the Gp120-aTexo vaccine may be an attractive 
candidate for the treatment of HIV-1 patients who suffer from CD4+ T cell deficiency. 
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CHAPTER 7 
FUTURE DIRECTIONS  
The development of efficient HIV-1 therapeutic vaccines is partly hindered by the 
lack of suitable animal models to test vaccine efficacy. It has been already shown that the 
Rag2-/-#C-/- double knockout model, which lacks B cells and NK cells (209, 210), is an 
excellent model for testing the immunotherapeutic effect of HIV vaccines (211, 212). The 
low dose irradiation (400 cGy) of newborn Rag2-/-#C-/- DKO mice can enhance human-
transgraft survival (213). Therefore, these mice can be reconstituted with human cord 
(CD34+) blood-derived hematopoietic stem cells (hHSC), which ultimately leads to the 
development of human B cells, T cells, monocytes, macrophage, and different DC 
subtypes (214). These cells together develop structures like lymphoid follicles in lymph 
nodes. CD4+ T cells present in the blood, spleen and bone marrow express both CCR5 
and CXCR4 chemokine receptors, which help to maintain viremia for longer period after 
introduction of HIV-1 infection. HIV-1 infection in Rag2-/-#C-/- DKO mice appears to 
follow a similar pathogenesis as in human patients.  
Gp120-aTexo vaccine can be further characterized efficiently in this model, where 
these DKO-hHSC-HIV mice produce active HIV-1 replication and virus-specific immune 
responses. These mice will be vaccinated with Gp120-aTexo prepared from A2-Kb-
derived CD8+ T cells to assess Gp120-specific effector and memory CD8+ T cell 
responses. Furthermore, the clearance of HIV-1 in the sera and different organs can be 
determined. 
Hepatitis C virus primarily causes liver infection. The chronic infection by this 
virus is associated with T-cell dysfunction. Currently, antiviral drugs are being used to 
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control hepatitis C virus disease progression. However, this therapy causes significant 
reduction in CD4+ T cell counts (210). Immunization of hepatitis C virus-specific 
CD8+aTexo vaccine in infected individuals’ could induce virus specific immune 
responses independent of CD4+ T cell but through acquired exosomal molecules. Hence, 
CD8+aTexo vaccine may be used in adjunction with antiviral therapy to induce hepatitis 
C virus-specific CD8+ CTL responses to control virus replication or disease progression. 
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